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ABSTRACT 
 
The aim of present work is to prepare floating tablets of famiotidne Hydrochloride 
using HPMC K4M, HPMC K15M and HPMC K100M as polymer. Floating drug 
delivery system have a bulk density less than gastric fluids and so remains buoyant in the 
stomach without affecting gastric emptying rate for a prolonged period of time. 
Famotidine an a histamine H2 receptor antagonist and used in the treatment of peptic 
ulcer disease (PUD) and gastroesophageal reflux disease (GERD). The short half life of 
famotidine, shorter resident in stomach and multiple administration dose make 
famotidine a very good candidate for formulation of floating drug delivery system. 
Floating tablets of famotidine were prepared by melt granulation method using HPMC 
K4M, HPMC K15M and HPMC K100M. The floating tablets was evaluated such as 
weight variation, hardness, friability, thickness, drug content, , invitro buoyancy, drug 
polymer compatibility (IR study ), and invitro dissolution studies of tablets. The 
micromeritic properties was found to be good, invitro buoyancy and invitro dissolution 
studies confirmed their good release nature. Formulation F4 prepared with of  HPMC 
K100M shows a good invitro buoyancy lag time & floating time and invitro dissolution 
studies shows a 96.78% release for a period of 12 hrs. The data obtained in this study 
thus suggest that a floating tablets of famotidine are promising for sustained drug 
delivery which can reduce dosing frequency. 
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1. INTRODUCTION 
Dosage forms that can be retained in the stomach are called gastro retentive drug 
delivery system(GRDDS).GRDDS can improve the controlled delivery of drugs that have 
an absorption window by continuously releasing the drug for a prolonged period of time 
before it reaches its absorption site.  
Oral controlled release (CR) dosage forms (DFs) have been developed over the 
past three decades due to their considerable therapeutic advantages such as ease of 
administration, patient compliance and flexibility in formulation. However, this approach 
is be dilled with several physiological difficulties such as inability to restrain and locate 
the controlled drug delivery system within the desired region of the gastrointestinal tract 
(GIT) due to variable gastric emptying and motility. Furthermore, the relatively brief 
gastric emptying time (GET) in humans which normally averages 2-3 h through the 
major absorption zone, i.e., stomach and upper part of the intestine can result in 
incomplete drug release from the drug delivery system leading to reduced efficacy of the 
administered dose(1). Therefore, control of placement of a drug delivery system (DDS) in 
a specific region of the GI tract offers advantages for a variety of important drugs 
characterized by a narrow absorption window in the GIT or drugs with a stability 
problem(2).  
These considerations have led to the development of a unique oral controlled 
release dosage form with gastro retentive properties. After oral administration, such a DF 
would be retained in the stomach and release the drug there in a controlled and prolonged 
manner, so that the drug could be supplied continuously to its absorption sites in the 
upper gastrointestinal      tract (3). Gastro retentive dosage form can remain in the gastric 
region for several hours and hence significantly prolong the gastric residence time of 
drugs. Prolonged gastric retention improves bioavailability, reduces drug waste, and 
improves solubility of drugs that are less soluble in a high pH environment. It is also 
suitable for local drug delivery to the stomach and proximal small intestines (4).  
Gastro retention helps to provide better availability of new products with suitable 
therapeutic activity and substantial benefits for patients. This mode of administration 
would best achieve the known pharmacokinetic and pharmacodynamic advantages of 
CR-DFs of these drugs. 
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The need for gastro retentive dosage forms (GRDFs) has led to extensive efforts 
in both academia and industry towards the development of such drug delivery systems. 
These efforts resulted in GRDFs that were designed, in large part, based on the following 
approaches: 
(a) Low density form of the DF that causes buoyancy in gastric fluid (5). 
(b) High density DF that is retained in the bottom of the stomach (6). 
(c) Bioadhesion to stomach mucosa (7). 
(d) Slowed motility of the gastrointestinal tract by concomitant administration of 
drugs or Pharmaceutical excipients(8, 9). 
(e) Expansion by swelling or unfolding to a large size which limits emptying of 
the DF through the pyloric sphincter (10).  
 
1.1. ANATOMY AND PHYSIOLOGY OF STOMACH 
Anatomy: 
The stomach is an organ for storage and mixing. Anatomically the stomach is 
divided into 3 regions: fundus, body, and antrum (pylorus). The proximal part made of 
fundus and body acts as a reservoir for undigested material, capable of displaying a large 
expansion to accomadate food without much increase in intragastric pressure. Whereas 
the antrum is the main site for mixing motions and act as a pump for gastric emptying by 
propelling actions. The opening nearer to esophagus is called as cardiac end characterized 
by pyrolic sphincter. Under fasting conditions the stomach is collapsed bag with residual 
volume of 50 ml and contains a small amount of gastric fluid and air.  
Physiology: 
            Stomach is an expanded section of digestive tube between theoesophagus and 
small intestine. The wall of the stomach is structurally similar to the other parts of the 
other parts of the digestive tube; with the exception the stomach have an extra, oblique 
layer of smooth muscle inside the circular layer which aids in performance of complex 
grinding motions. 
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Fig.no.1. Internal structure of stomach 
            There are images to four types of secretary epithelial cells that cover the surface 
of the stomach and extended down into gastric pits and glands: 
• Mucous cells: secrete alkaline mucous that protects epithelium against 
shear stress and acid. 
• Parietal cells: secrete hydrochloric acid. 
• Chief cells: secrete pepsin, a proteolytic enzyme. 
• G cells secrete the hormone gastrin. The contraction of gastric smooth 
muscle serves two basic functions. 
a. Ingested food is crushed, ground, mixed and liquefying to form chime. 
b. Chime is forced through the pyloric canal in to the small intestine, a 
process called gastric emptying. 
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Mucosa: 
When stomach is empty the mucous membrane lining is thrown in longitudinal 
folds or rugae, and when full the rugae are ignored out and the surface is a smooth 
velvety appearance there are numerous gastric glands situated below the surface in the 
mucous membrane consisting of the specialized cells that secrete gastric juice into the 
stomach. 
Nerve supply: 
The sympathetic supply to the stomach is mainly from coeliac plexus and 
parasympathetic supply is from vagus nerves. Sympathetic stimulation reduces motility 
of the stomach Under the physiological conditions, the gastric absorption of the drugs are 
insignificant as a result of the limited surface area covered by a thick layer of mucosal 
coating, the lack of villi on the mucosal surface, and the short residence time of the drugs 
in the stomach. 
 
Blood supply: 
 Arterial blood is supplied to the stomach by branches of coeliac artery and venous 
drainage into the portal vein. 
 
Gastric juice composition: 
About 2 to 3 liters of gastric juice secreted daily by specialized cells in the 
mucosa. About 60ml with approximately 4 mmol of hydrogen ions per hour.  
It consists of, 
• Water 
• Gastric enzymes(Pepsin, Gastric Lipase, Gastrin, Renin and other 
enzymes) 
• Mucus- Glycoprotein 
 
• Intrinsic factor 
• Hydrochloric acid, Sodium, Calcium, Potassium, Chloride, Bicarbonate, 
Phosphate and Sulfate 
 
 
 CHAPTER 1                                                                                                                       INTRODUCTION 
Dept. of Pharmaceutics                                                                    J.K.K.Nattraja College of Pharmacy 
 
5
Features of upper GIT: 
 
Table no.1. Features of upper GIT 
Where,   
P – Passive diffusion.                             
C – Aqueous Channel transport. 
A – Active transport.                            
F – Facilitated transport.  
I – Ion-pair transport.                           
E – Entero (or) pinocytosis.  
Gastric pH:      
Fasted healthy subject: 1.1 ± 0.15.  
Fed healthy subject:3.6 ± 0.4. 
Volume    :      Resting volume is about 25-50 ml.  
Gastric emptying and motility: 
Gastric emptying occurs during fasting as well as fed states. The passage of drug 
from stomach to the small intestine is called gastric emptying. It is the rate limiting step 
Section Length(m) Transit time(t) P
H
 
Microbial 
count 
Absorbing 
surface 
area(m2) 
Absorption 
pathway 
Stomach 0.2 Variable 1-4 ≤103 0.1 P,C,A 
Small 
intestine 
10-6 3±1 5-7.5 103-1010 120-200 P,C,A,F,I,E,CM 
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for drug absorption because the major site for absorption in intestine. Generally rapid 
gastric emptying increase bioavailability of the drug. Faster onset requires for drugs that 
degrade in gastric environment. Delayed gastric emptying promotes dissolution of the 
drugs, which are poorly soluble drugs and for the drugs that is majorly absorbed from 
stomach or proximal part of the intestine. The pattern of motility is however distinct in 
the 2 states. During the fasting state an inter digestive series of electrical events take 
place, which cycle both through stomach and intestine every 2 to 3 hours. This is called 
the inter digestive myloelectric cycle or migrating myloelectric cycle (MMC), which is 
further divided into following 4 phases are, 
 Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions.  
 Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action 
potential and contractions. As the phase progresses the intensity and 
frequency also increases gradually.  
 Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and 
regular contractions for short period. It is due to this wave that all the 
undigested material is swept out of the stomach down to the small 
intestine. It is also known as the housekeeper wave.  
 Phase IV Period of transition from phase III and phase I last for 0 to 5 
minutes. 
 After the ingestion of a mixed meal, the pattern of contractions changes from 
fasted to that of fed state. This is also known as digestive motility pattern and comprises 
continuous contractions as in phase II of fasted state. These contractions result in 
reducing the size of food particles (to less than 1 mm), which are propelled toward the 
pylorus in a suspension form. During the fed state onset of myloelectric cycle (MMC) is 
delayed resulting in slowdown of gastric emptying rate (11).  
       Many Scintigraphic studies determining gastric emptying rates revealed that orally 
administered controlled release dosage forms are subjected to basically 2 complications, 
that of short gastric residence time and unpredictable gastric emptying rate. 
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Gastric Transit time: 
The transit time of gastrointestinal drug delivery system along GI tract is the most 
limiting physiological factor in the development of controlled- release gastrointestinal 
drug delivery systems. The pattern of GI transit depends on the fasted or fed state.  
 
 
 
 
 
 
Fig no.2. Phase cycle 
Requirements for gastric retention:  
Physiological factors in the stomach it must be noted that to achieve gastric 
retention, the dosage form must satisfy certain requirements (12). One of the key issues is 
that the dosage form must be able to withstand the forces caused by peristaltic waves in 
the stomach and the constant contractions and grinding and churning mechanisms. To 
function as a gastric retention device, it must be resist premature gastric emptying. 
Furthermore, once its purpose has been served, the device should be removed from the 
stomach with ease.  
 
1.2. SUITABLE DRUG CANDIDATES FOR GASTRORETENTION 
In general, appropriate candidates for CRGRDF are molecules that have poor 
colonic absorption but are characterized by better absorption properties at the upper parts 
of the GIT: 
 Drugs acting locally in the stomach, 
 E.g., Antacids and drugs for H. Pylori viz., Misoprostol 
 Drugs that are primarily absorbed in the stomach, 
 E.g., Amoxicillin 
 Drugs that is poorly soluble at alkaline PH, 
 E.g., Furosemide, Diazepam, Verapamil, etc. 
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 Drugs with a narrow window of absorption, 
 E.g., Cyclosporine, Methotrexate, Riboflavin and Levodopa, etc. 
 Drugs which are absorbed rapidly from the GI tract, 
 E.g., Metronidazole, Tetracycline. 
 Primarily absorbed from stomach and upper part of GItract,  
 E.g., Calcium supplements, Chlordiazepoxide and Cinnarazine 
 Drugs that degrade in the colon(13), 
 E.g. Ranitidine, Metformin HCl, Metronidazole. 
 Drugs that disturb normal colonic microbes, 
 E.g. Amoxicillin trihydrate - Antibiotics against Helicobacter pylori. 
 
 
1.3. DRUGS THOSE ARE UNSUITABLE FOR GASTRORETENTIVE DRUG 
DELIVERY SYSTEMS 
 Drugs that have very limited acid solubility (13). 
 E.g. Phenytoin etc. 
 Drugs that suffer instability in the gastric environment. 
 E.g. Erythromycin etc. 
 Drugs intended for selective release in the colon. 
 E.g. 5- amino salicylic acid and Corticosteroids etc. 
 
1.4. Factors affecting the gastro retentive system (11) 
Various attempts have been made to retain the dosage form in the stomach as a 
way of increasing the retention time. These attempts include use of floating dosage forms 
(gas-generating systems and swelling or expanding systems), mucoadhesive systems, 
high-density systems, modified shape systems, gastric emptying delaying devices and co-
administration of gastric-emptying delaying drugs. Most of these approaches are 
influenced by a number of factors that affect their bioavailability and efficacy of the 
gastro retentive system (11). 
 
1. Density: Density of a dosage form plays a vital role in determining its buoyancy 
and henceforth, its floating efficiency. 
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2. Shape of dosage form: Compared to other shapes, devices with tetrahedron and 
ring shape have better floating potential. They have 90-98% better retention for 24 
hrs. 
3. Single or multiple unit formulation: Multiple unit formulations permit a larger 
margin of safety against dosage form failure compared with single unit dosage 
forms. Multiple unit formulations show a more predictable release profile and 
negligible impairing of performance due to failure of units. 
4. Fed or unfed state: Under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex (MMC) 
that occurs every 1.5 to 2 hours. 
5. Nature of meal: Feeding of indigestible polymers or fatty acid salts can change 
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release (11). 
6. Caloric content: A meal rich in protein and fat content can increase floating by 4-
10 hrs.  
7. Frequency of feed: The floating can increase by over 400 minutes when 
successive meals are given compared with a single meal. 
8. Age: Elderly people, above the age of 60, have a significantly longer floating. 
9. Posture: Floating varies considerably between supine and upright ambulatory 
states of the patient. 
10. Concomitant drug administration: Anticholinergics like Atropine, Opiates like 
Codeine and Prokinetic agents like Metoclopramide and Cisapride affect floating 
time.  
11. Biological factors: Floating may vary as per health conditions or physiological 
status of a person.eg. Diabetes and Crohn’s disease alters floating time.  
FACTORS AFFECFLOATING AND FLOATING TIME 
1.5. Formulation considerations for GRDDS (14) 
It must be effective retention in the stomach to suit for the clinical demand 
1) It must have sufficient drug loading capacity. 
2) It must be control the drug release profile. 
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3) It must have full degradation and evacuation of the system once the drug release 
is over(14). 
4) It should not have effect on gastric motility including emptying pattern. 
5) It should not have other local adverse effects. 
 
1.5.1. Polymers and other ingredients (14) 
Following types of ingredients can be incorporated into HBS dosage form in 
addition to the drugs: 
Hydrocolloids (20%-75%): They can be synthetics, anionic or non-ionic like 
hydrophilic gums, modified cellulose derivatives.  
Eg. Acacia, Pectin, Chitosan, Agar, Casein, Bentonite, Veegum, HPMC (K4M, K100M 
andK15M), Gellan gum (Gelrite®), Sodium CMC, MC, HPC. 
Inert fatty materials (5%-75%): Edible, inert fatty materials having a specific gravity 
of less than one can be used to decrease the hydrophilic property of formulation and 
hence increase buoyancy.  
E.g. Beeswax, Fatty acids, Long chain fatty alcohols, Gelucires®  39/01 and 43/01. 
Effervescent agents: Sodium bicarbonate, Citricacid, Tartaric acid, Di-SGC (Di-Sodium 
GlycineCarbonate, CG (Citroglycine). 
Release rate accelerants (5%-60%): eg.Lactose,Mannitol. 
Release rate retardants (5%-60%): eg. Dicalciumphosphate, Talc, Magnesium stearate. 
Buoyancy increasing agents (upto80%): eg. Ethylcellulose. 
Low density material: Polypropylene foampowder (Accurel MP 1000®). 
 
1.5.2. Advantages of gastroretentive delivery systems (17-19) 
 Improvement of bioavailability and therapeutic efficacy of the drugs and possible 
reduction of dose e.g. Furosemide. 
 Maintenance of constant therapeutic levels over a prolonged period and thus 
reduction in fluctuation in therapeutic levels minimizing the risk of resistance 
especially in case of antibiotics. E.g. β-lactam antibiotics (Penicillins and 
Cephalosporins) (17). 
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 For drugs with relatively short half life, sustained release may result in a flip- flop 
pharmacokinetics and also enable reduced frequency of dosing with improved 
patient Compliance. 
 They also have an advantage over their conventional system as it can be used to 
overcome the adversities of the gastric retention time (GRT) as well as the gastric 
emptying time (GET). As these systems are expected to remain buoyant on the 
gastric fluid without affecting the intrinsic rate of employing because their bulk 
density is lower than that of the gastric fluids (18). 
 Gastro retentive drug delivery can produce prolongs and sustains release of drugs 
from dosage forms which avail local therapy in the stomach and small intestine. 
Hence they are useful in the treatment of disorders related to stomach and small 
intestine. 
 The controlled, slow delivery of drug form gastro retentive dosage form provides 
sufficient local action at the diseased site, thus minimizing or eliminating 
systemic exposure of drugs. This site specific drug delivery reduces undesirable 
Effects of side effects. 
 Gastro retentive dosage forms minimize the fluctuation of drug concentrations 
and effects. Therefore, concentration dependent adverse effects that are associated 
with peak concentrations can be presented. This feature is of special importance 
for drug with a narrow therapeutic index (19). 
 Gastro retentive drug delivery can minimize the counter activity of the body 
leading to higher drug efficiency. 
 Reduction of fluctuation in drug concentration makes it possible to obtain 
improved selectivity in receptor activation. 
 The sustained mode of drug release from Gastro retentive doses form enables 
extension of the time over a critical concentration and thus enhances the 
pharmacological effects and improves the chemical outcomes. 
 
1.5.3. Disadvantages of floating drug delivery system (17): 
 Floating system is not feasible for those drugs that have solubility or stability 
problem in G.I. tract. 
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 These systems require a high level of fluid in the stomach for drug delivery to 
float and work efficiently-coat, water (17). 
 The drugs that are significantly absorbed through out gastrointestinal tract, which 
undergo significant first pass metabolism, are only desirable candidate.  
 Some drugs present in the floating system causes irritation to gastric mucosa. 
 
1.5.4. LIMITATIONS (18, 19):  
 Require a higher level of fluids in the stomach (18). 
 Not suitable for Drugs that. 
• Have solubility problems in gastric fluid. E.g. Phenytoin, 
• Cause G.I irritation. E.g. NSAIDS, 
• Are unstable in acidic environment. 
 Drugs intended for selective release in the colon E.g. 5- amino salicylic acid and 
Corticosteroids etc. 
 The floating systems in patients with achlorhydria can be questionable in case of 
swell able system (18). 
 Retention of high density systems in the antrum part under the migrating waves of 
the stomach is questionable. 
 The mucus on the walls of the stomach is in a state of constant renewal, resulting 
in unpredictable adherence. 
 The mucus on the walls of the stomach is in a state of constant renewal, resulting 
in unpredictable adherence (19). 
 
1.5.5. Application of gastro retentive drug delivery systems (20) 
 Enhanced bioavailability 
The bioavailability of riboflavin CR-GRDF is significantly enhanced in 
comparison to the administration of non-GRDF CR polymeric formulations. 
There are several different processes, related to absorption and transit of the drug 
in the gastrointestinal tract, that act concomitantly to influence the magnitude of 
drug absorption. Drugs that have poor bioavailability because of site specific 
absorption from the upper part of the gastrointestinal tract are potential candidates 
to be formulated as floating drug delivery systems, thereby maximizing their 
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absorption (20).  
Eg. A significantly increase in the bioavailability of floating dosage forms(42.9%) 
could be achieved as compared with commercially available LASIX tablets 
(33.4%) and enteric coated LASIX-long product (29.5%). 
 
 Enhanced first-pass biotransformation 
In a similar fashion to the increased efficacy of active transporters 
exhibiting capacity limited activity, the pre-systemic metabolism of the tested 
compound may be considerably increased when the drug is presented to the 
metabolic enzymes (cytochrome P450, in particular CYP3A4) in a sustained 
manner, rather than by a bolus input. 
 
 Sustained drug delivery/reduced frequency of dosing 
For drugs with relatively short biological half life, sustained and slow 
input from CR-GRDF may result in a flip-flop pharmacokinetics and enable 
reduced dosing frequency. This feature is associated with improved patient 
compliance, and thereby improves therapy (20). 
E.g. Sustained release floating capsules of nicardipine hydrochloride were 
developed and were evaluated in vivo. The formulation compared with 
commercially available MICARD capsules using rabbits. Plasma concentration 
time curves showed a longer duration for administration (16 hours) in the 
sustained release floating capsules as compared with conventional MICARD 
capsules (8 hours). 
 
 Targeted therapy for local ailments in the upper GIT 
The prolonged and sustained administration of the drug from GRDF to the 
stomach may be advantageous for local therapy in the stomach and small 
intestine. By this mode of administration, therapeutic drug concentrations may be 
attained locally while systemic concentrations, following drug absorption and 
distribution, are minimal. 
 
 Reduced fluctuations of drug concentration 
Continuous input of the drug following CRGRDF administration produces 
blood drug concentrations within a narrower range compared to the immediate 
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release dosage forms. Thus, fluctuations in drug effects are minimized and 
concentration dependent adverse effects that are associated with peak 
concentrations can be prevented. This feature is of special importance for drugs 
with a narrow therapeutic index (20). 
 
 Improved selectivity in receptor activation 
Minimization of fluctuations in drug concentration also makes it possible 
to obtain certain selectivity in the elicited pharmacological effect of drugs that 
activate different types of receptors at different concentrations. 
 
 Reduced counter-activity of the body 
In many cases, the pharmacological response which intervenes with the 
natural physiologic processes provokes a rebound activity of the body that 
minimizes drug activity. Slow input of the drug into the body was shown to 
minimize the counter activity leading to higher drug efficiency (20). 
 
 Extended time over critical (effective) concentration 
For certain drugs that have non-concentration dependent 
pharmacodynamics, such as betalactam antibiotics, the clinical response is not 
associated with peak concentration, but rather with the duration of time over a 
critical therapeutic concentration. The sustained mode of administration enables 
extension of the time over a critical concentration and thus enhances the 
pharmacological effects and improves the clinical outcomes. 
 
 Minimized adverse activity at the colon 
Retention of the drug in the GRDF at the stomach minimizes the amount 
of drug that reaches the colon. Thus, undesirable activities of the drug in colon 
may be prevented. This pharmacodynamic aspect provides the rationale for GRDF 
formulation for β-lactam antibiotics that are absorbed only from the small 
intestine, and whose presence in the colon leads to the development of 
microorganism’s resistance. 
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 Site specific drug delivery 
A floating dosage form is a feasible approach especially for drugs which 
have limited absorption sites in upper small intestine. The controlled, slow 
delivery of drug to the stomach provides sufficient local therapeutic levels and 
limits the systemic exposure to the drug. This reduces side effects that are caused 
by the drug in the blood circulation. In addition, the prolonged gastric availability 
from a site directed delivery system may also reduce the dosing frequency. These 
systems are particularly advantageous for drugs that are specifically absorbed 
from stomach or the proximal part of the small intestine, eg, Riboflavin and 
Furosemide. 
E.g. Furosemide is primarily absorbed from the stomach followed by the 
duodenum. It has been reported that a monolithic floating dosage form with 
prolonged gastric residence time was developed and the bioavailability was 
increased. AUC obtained with the floating tablets was approximately 1.8 times 
those of conventional Furosemide tablets. 
 
1.6. Approaches to gastric retention (21 ) 
Various attempts have been made to retain the dosage form in the stomach as a 
way of increasing the retention time. These attempts include introducing floating dosage 
forms (gas generating systems). Swelling and expanding systems, Mucoadhesive 
systems, High density systems, Modified shape systems, Gastric emptying delaying 
devices and co-administration of gastric delaying drugs. Among these, the floating 
dosage forms have been used most    commonly (21). 
Floating DDS (FDDS), with low density providing sufficient buoyancy to float 
over the gastric contents, Bioadhesive systems, enabling the localized retention of the 
system in the stomach, Swelling and expanding systems, preventing transit from the 
gastric sphincter, High density system, remaining in the stomach for longer period of 
time by sedimenting to the folds of stomach, Super porous hydro gels, and Modified-
shaped system. A number of other methods like use of passage-delaying agents, 
magnetically controlled systems and combination methods like floating-bioadhesive 
systems. 
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Floating drug delivery systems 
FDDS have a bulk density less than gastric fluids and so remain buoyant in the 
stomach without affecting the gastric emptying rate for a prolonged period of time. While 
the system is floating on the gastric contents the drug is released slowly at the desired rate 
from the system. This results in an increased GRT and a better control of fluctuations in 
plasma drug concentration. The device must have sufficient structure to form a cohesive 
gel barrier, it must maintain an overall specific gravity lower than that of gastric contents 
(1.004-1.010) and it should dissolve slowly enough to serve as a drug reservoir. 
 
Types of floating drug delivery systems 
Based on the mechanism of buoyancy and two distinctly different technologies 
have been utilized in the development of FDDS.  
1) Non- Effervescent FDDS  
2) Effervescent FDDS 
 
1) Non-Effervescent FDDS 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion tomucosal layer in GI tract. The most commonly used excipients in non-
effervescent FDDS are gel forming or highly swellable Cellulose type hydrocolloids, 
Hydrophilic gums, Polysaccharides and Matrix forming materials such as Polycarbonate, 
Polyacrylate, Polymethacrylate, Polystyrene as well as Bioadhesive polymers such as 
Chitosan and Carbopol(21).  
The various types of this system are as: 
A. Single Layer Floating Tablets 
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than unity. 
They are formulated by intimate mixing of drug with low-density enteric materials such 
as CAP, HPMC. 
 
 CHAPTER 1                                                                                                                       INTRODUCTION 
Dept. of Pharmaceutics                                                                    J.K.K.Nattraja College of Pharmacy 
 
17
 
Fig. no.3. Single layer tablets 
B. Bi-layer Floating Tablets 
A bi-layer tablet contain two layer one immediate release layer which releases 
initial dose fromsystem while the another sustained release layer absorbs gastric fluid, 
forming an impermeable colloidal gelbarrier on its surface, and maintain a bulk density of 
less than unity and thereby it remains buoyant in the stomach(21). 
 
Fig.no.4. Bilayer floating tablets 
C. Alginate Beads  
Multi-unit floating dosage forms were developed from freeze-dried Calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared by dropping 
Sodium alginate solution into aqueous solution of Calcium chloride, causing precipitation 
of Calcium alginate leading to formation of porous system, which can maintain a floating 
force for over 12 hours. When compared with solid beads, which gave a short residence 
time of 1 hour, and these floating beads gave a prolonged residence time of more than 5.5 
hours. 
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D. Hollow Microspheres 
Hollow microspheres (microballoons), loaded with drug in their outer polymer 
shells are prepared by a novel emulsion-solvent diffusion method. The Ethanol: 
Dichloromethane solution of the drug and an enteric acrylic polymer is poured into an 
agitated aqueous solution of PVA that is thermally controlled at4000C. The gas phase 
generated in dispersed polymer droplet by evaporation of dichloromethane forms an 
internal cavity in microsphere of polymer with drug. The microballoons float 
continuously over the surface of acidic dissolution media containing surfactant for more 
than 12 hours in vitro. 
 
Fig.no.5. Hollow microsphere or microballoons 
 
2) Effervescent System 
Effervescent systems include use of gas generating agents, carbonates (ex. 
Sodium bicarbonate) and other organic acid (e.g. Citric acid and Tartaric acid) present in 
the formulation to produce Carbon dioxide (CO2) gas, thus reducing the density of the 
system and making it float on the gastric fluid. An alternative is the incorporation of 
matrix containing portion of liquid, which produce gas that evaporates at body 
temperature. These effervescent systems further classified into two types:  
1. Gas generating systems, 
2. Volatile Liquid/Vacuum Containing Systems. 
1. Gas Generating Systems 
A. Tablets 
Floating bilayer tablets with controlled release for Furosemide were developed by 
Ozdemir et al., 2000. The low solubility of the drug could be enhanced by using the 
kneading method, preparing a solid dispersion with β cyclodextrin mixed in a 1:1 ratio. 
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One layer contained the polymers HPMC K4M, HPMC K100M and CMC (for the 
control of the drug delivery) and the drug. The second layer contained the effervescent 
mixture of sodium bicarbonate and citric acid. The in vitro floating studies revealed that 
the lesser the compression force the shorter is the time of onset of floating, i.e., when the 
tablets were compressed at 15 MPa, these could begin to float at 20 minutes whereas at a 
force of 32 MPa the time was prolonged to 45 minutes(21). Radiographic studies on 6 
healthy male volunteers revealed that floating tablets were retained in stomach for 6 
hours and further blood analysis studies showed that bioavailability of these tablets was 
1.8 times that of the conventional tablets. On measuring the volume of urine the peak 
diuretic effect seen in the conventional tablets was decreased and prolonged in the case of 
floating dosage form. 
 
B. Floating capsules 
Floating capsules are prepared by filling with a mixture of sodium alginate and 
sodium bicarbonate. The systems were shown to float during in vitro tests as a result of 
the generation of CO2 that was trapped in the hydrating gel network on exposure to an 
acidic environment. 
 
Fig.no.6. Effervescent (gas generating) system 
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Fig.no.7. Drug release from gas generating system 
 
C. Multiple unit type floating pills 
The system consists of sustained release pills as ‘seeds’ surrounded by double 
layers. The inner layer consists of effervescent agents while the outer layer is of swell 
able membrane layer. When the system is immersed in dissolution medium at body temp, 
it sinks at once and then forms swollen pills like balloons, which float as they have lower 
density. This lower density is due to generation and entrapment of CO2 within the system. 
 
D. Floating system with Ion-Exchange resins 
A floating system using ion exchange resin that was loaded with bicarbonate by 
mixing the beads with 1M sodium bicarbonate solution. The loaded beads were then 
surrounded by a semi permeable membrane to avoid sudden loss of CO2. Upon coming in 
contact with gastric contents an exchange of chloride and bicarbonate ions took place that 
resulted in CO2 generation thereby carrying beads toward the top of gastric contents and 
producing a floating layer of resin beads. The in vivo behavior of the coated and uncoated 
beads was monitored using a single channel analyzing study in 12 healthy human 
volunteers by gamma radio scintigraphy. Studies showed that the gastric residence time 
was prolonged considerably (24 hours) compared with uncoated beads (1 to 3 hours). 
 
2. Volatile Liquid / Vacuum Containing Systems 
A. Intra-gastric floating gastrointestinal drug delivery system 
These systems can be made to float in the stomach because of floatation chamber, 
which may be a vacuum or filled with air or a harmless gas, while drug reservoir is 
encapsulated inside a micro-porous compartment. 
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Fig.no.8. Intra-gastric drug delivery system 
 
B. Inflatable gastrointestinal delivery systems 
In these systems an inflatable chamber is incorporated, which contains liquid 
ether that gasifies at body temperature to cause the chamber to inflate in the stomach. 
These systems are fabricated by loading the inflatable chamber with a drug reservoir, 
which can be a drug impregnated polymeric matrix, encapsulated in a gelatin capsule.  
After oral administration, the capsule dissolves to release the drug reservoir 
together with the inflatable chamber. The inflatable chamber automatically inflates and 
retains the drug reservoir compartment in the stomach. The drug continuously released 
from the reservoir into the gastric fluid. 
 
 
Fig.no.9. Inflatable drug delivery system 
 
C. Intragastric osmotically controlled drug delivery system 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a biodegradable capsule. In the stomach, the capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device.  
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The inflatable support inside forms a deformable hollow polymeric bag that 
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic pressure 
controlled drug delivery device consists of two components; drug reservoir compartment 
and an osmotically active compartment. The drug reservoir compartment is enclosed by a 
pressure responsive collapsible bag, which is impermeable to vapor and liquid and has a 
drug delivery orifice.  
The osmotically active compartment contains an osmotically active salt and is 
enclosed within a semipermeable housing. In the stomach, the water in the GI fluid is 
continuously absorbed through the semipermeable membrane into osmotically active 
compartment to dissolve the osmotically active salt.  
The osmotic pressure thus created acts on the collapsible bag and in turn forces 
the drug reservoir compartment to reduce its volume and activate drug release through 
the delivery orifice.  
The floating support is also made to contain a bioerodible plug that erodes after a 
predetermined time to deflate the support. The deflated drug delivery system is then 
emptied from the stomach. 
 
Fig.no.10. Intragastric osmotically CDDS 
 
Bioadhesive drug delivery system 
The term bioadhesion is defined as adhesion to biological surface i.e. mucus 
and/or mucosal surface. In instances when the polymeric system interacts with mucus 
layer only, it is referred as mucoadhesion. In order to develop an ideal oral bioadhesive 
system, it is important to have a thorough understanding of mucosa, bioadhesive 
polymers and mucin-polymer interactions in the physiological environment. 
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Intestinal mucosa is composed of high molecular weight glycoproteins hydrated 
and covering the mucosa with a continuous adherent blanket. Mucin glycoproteins are 
rich with fucose and sialic acid groups at the terminal ends which provide a net negative 
charge in the acidic environment. The thickness of the mucin gel layer varies in different 
regions of the GIT with thickness ranging between 50-500 µm in stomach to 15-150µm 
in the colon. Cohesion of the mucin gel is dependent upon the glycoprotein 
concentration. The mucus layer is created biologically to play a number of important 
functions of protecting the underlying tissues from various diffusing/corrosive elements 
such as enzymes, acid and other toxic molecules. Also being a visco-elastic gel, it helps 
in the passage of food over the epithelium, thereby minimizing potential erosive damages 
(21)
. The mucus layer, in addition to providing protection, provides a barrier to drug 
absorption. Various investigators have proposed different mucin-polymer interactions, 
such as Wetting and swelling of the polymer to permit intimate contact with the 
biological tissue. Interpenetration of bioadhesive polymer chains and entanglement of 
polymer and mucin chains. Formation of weak chemical bonds sufficient polymer 
mobility to allow spreading Water transport followed by mucosal dehydration. 
As the mucus layer comes into contact with bioadhesive coated system, various 
non-specific (Vander Waals, hydrogen bonding and/or hydrophobic interactions) or 
specific interactions occur between the complimentary structures. However, these 
interactions last only until the turnover process of mucin and, in order for a bioadhesive 
system to be successful; it should release its drug contents during this limited adhesion 
time. 
 
Raft-forming systems 
Here, a gel-forming solution (e.g. sodium alginate solution containing carbonates 
or bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2 
bubbles on contact with gastric fluid. Formulations also typically contain antacids such as 
aluminium hydroxide or calcium carbonate to reduce gastric acidity. Because raft-
forming systems produce a layer on the top of gastric fluids, they are often used for 
gastro esophageal reflux treatment as with liquid gaviscon. 
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Fig.no.11. Barrier formed by raft-forming system 
 
Low density systems 
Gas-generating systems inevitably have a lag time before floating on the stomach 
contents, during which the dosage form may undergo premature evacuation through the 
pyloric sphincter.  
Low-density systems (<1 g/cm3) with immediate buoyancy have therefore been 
developed. They are made of low-density materials, entrapping oil or air. Most are 
multiple unit systems, and are also called ‘‘microballoons’’ because of the low-density 
core.  
 
Fig.no.12. Low density system 
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Generally, techniques used to prepare hollow microspheres involve simple solvent 
evaporation or solvent diffusion methods. Polycarbonate, Eudragit S, cellulose acetate, 
calcium alginate, agar and low methoxylated pectin are commonly used as polymers.  
Buoyancy and drug release are dependent on quantity of polymer, the plasticizer–
polymer ratio and the solvent used. 
 
Expandable systems 
A dosage form in the stomach will withstand gastric transit if it is bigger than the 
pyloric sphincter. However, the dosage form must be small enough to be swallowed, and 
must not cause gastric obstruction either singly or by accumulation. Thus, three 
configurations are required, a small configuration for oral intake, an expanded 
gastroretentive form and a final small form enabling evacuation following drug release.  
Unfold able systems are made of biodegradable polymer; the concept is to make a 
carrier, such as a capsule, incorporating a compressed system, which extends in the 
stomach. Caldwell et al., 1988 proposed different geometric forms (tetrahedron, ring or 
planar membrane (4-lobed, disc or 4-limbed cross form) of biodegradable polymer 
compressed within a capsule. 
 
Swellable System 
Swellable systems are also retained because of their mechanical properties. The 
swelling usually results from osmotic absorption of water. The dosage form is small 
enough to be swallowed, and swells in gastric liquids, the bulk enable gastric retention 
and maintains the stomach in a ‘fed’ state, suppressing housekeeper waves. 
 
Fig.no.13. Drug release from swellable system 
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Superporous hydrogels 
Although these are swellable systems, they differ sufficiently from the 
conventional types to warrant separate classification with pore size ranging between 10 
nm and 10 µm. Absorption of water by conventional hydrogel is very slow process and 
several hours may be needed to reach an equilibrium state during which premature 
evacuation of the dosage form may occur(21).  
Superporous hydrogel, average pore size > 100 µm, swell to equilibrium size 
within a minute, due to rapid water uptake by capillary wetting through numerous 
interconnected open pores. Moreover they swell to a large size (swelling ratio 100 or 
more) and are intended to have sufficient mechanical strength to withstand pressure by 
gastric contractions. This is achieved by a co- formulation of a hydrophilic particulate 
material, Ac-Di- Sol (crosscarmellose sodium). 
 
Magnetic system 
These systems appear as small gastroretentive capsules containing a magnetic 
material, whose elimination from the stomach is prevented by the interaction with a 
sufficiently strong magnet applied to the body surface in the region of the stomach.  
Despite numerous reports about successful tests, the real applicability of such 
systems is doubtful because the desired results can be achieved only provided that the 
magnet position is selected with very high precision. Probably, the development of new 
conveniently applied magnetic field sources will improve this concept. 
 
Self-unfolding systems 
The self-unfolding systems are capable of mechanically increasing in size relative 
to the initial dimensions. This increase prevents the system from passing via the pylorus 
and provides for its prolonged stay in the stomach.  
A drug can be either contained in a polymeric composition of the gastroretentive 
system or included as a separate component. Several methods were suggested to provide 
for the self-unfolding effect (21). 
(1) The use of hydrogels swelling in contact with the gastric juice. 
(2) Osmotic systems, comprising an osmotic medium in a semipermeable membrane. 
(3) Systems based on low-boiling liquids converting into a gas at the body temperature. 
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High density systems 
Gastric contents have a density close to water (1.004 g /cm3). When the patient is 
upright small high-density pellets sink to the bottom of the stomach where they become 
entrapped in the folds of the antrum and withstand the peristaltic waves of the stomach 
wall(21).  
A density close to 2.5 g/cm3 seems necessary for significant prolongation of 
gastric residence time and Barium sulphate, Zinc oxide, Iron powder, Titanium dioxide 
are used as excipients. 
1.7.FORMULATION INGREDIENTS OF FLOATING DOSAGE 
FORM100 
Following types of the ingredients can be incorporated in to floating dosage 
form, 
a) Hydrocolloids 
b) Inert fatty materials 
c) Release rate accelerants 
d) Release rate retardant 
e) Buoyancy increasing agents  
f) Low density material 
g) Miscellaneous 
a.  Hydrocolloids: Suitable hydrocolloids are synthethics, anionic or non ionic like 
hydrophilic gumes, modified cellulose derivatives. E.g. Accasia, pectin, agar, alginates, 
gelatin, casein, bentonite, veegum, MC, HPC, HEC, and Na CMC can be used. The 
hydrocolloids must hydrate in  acidic medium i.e. gastric fluid is having pH 
1.2.Although the bulk density of the formulation may initially be more than one, but 
when gastric fluid is enter in the system, it should be hydrodynamically balanced to 
have a bulk density of less than one to assure buoyancy. 
b.  Inert   fatty   materials:   Edible,   pharmaceutical   inert   fatty material, having a 
specific gravity less than one can be added to the formulation to decrease the 
hydrophilic property of formulation andhence increases the buoyancy. Example: 
Purified grades of beeswax, fatty acids, long chain alcohols, glycerides, and minaral oils 
can be used. 
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c.  Release rate accelerants:  The release rate of the medicament from the formulation 
can be modified by including excipient like lactose and/or mannitol. These may be 
present from about 5-60% by weight. 
d.  Release rate retardant:  Insoluble substances such as dicalcium phosphate, talc, 
magnesium strearete decresesd the solubility and hence retard the release of 
medicaments. 
e.  Buoyancy  increasing  agents:    Materials like ethyl  cellulose, which has bulk 
density less than one, can be used for enhancing the buoyancy of the formulation. It 
may be adapted up to 80 % by weight. 
f.   Low density material:  Polypropylene foam powder 
g. Miscellaneous: Pharmaceutically acceptable adjuvant like preservatives, stabilizers, 
and lubricants can be incorporates in the dosage forms as per the requirements. They do 
not adversely affect the hydrodynamic balance of the systems 
1.8.EVALUATION PARAMETERS OF FDDS 
Different    studies    reported    in    the    literature    indicate    that 
pharmaceutical dosage forms exhibiting gastric residence in vitro floating   behavior   
show   prolonged   gastric   residence   in   vivo. However, it has to be pointed out that 
good in vitro floating behavior alone is not sufficient proof for efficient gastric 
retention in vivo. The effects of the simultaneous presence of food and of the complex 
motility of the stomach are difficult to estimate. Obviously, only in vivo studies can 
provide definite proof that prolonged gastric residence is obtained. 
Floating time:    
The test for floating time is usually performed in simulated gastric fluid or 0.1 
mole.lit-1  HCl maintained at 37°C, by using USP dissolution apparatus containing 900 
ml of 0.1 molar HCl as the dissolution medium. The time taken by the dosage form to 
float is termed as floating lag time and the time for which the dosage form floats is 
termed as the floating or flotation time. 
Drug release:  
Dissolution tests are performed using the dissolution apparatus. Samples are 
withdrawn periodically from the dissolution medium with replacement and then 
analyzed for their drug content  after an appropriate dilution. 
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Drug loading, drug entrapment efficiency, particle size analysis, surface 
characterization(for floating microspheres and beads):  
Drug loading is assessed by crushing accurately weighed sample of beads or  
microspheres in  a mortar  and added  to the appropriate dissolution medium which is 
then centrifuged, filtered and analyzed by   various   analytical   methods   like   
spectrophotometry.   The percentage drug loading is calculated by dividing the amount 
of drug in the sample by the weight of total beads or microspheres. The particle size 
and the size distribution of beads or microspheres is determined in the dry state 
using the optical microscopy method. The     external     and     cross-sectional     
morphology     (surface characterization) is done by scanning electron microscope 
(SEM). 
 Measurement of buoyancy capabilities of the FDDS 
The floating behaviour was evaluated with resultant weight measurements. The 
experiment was carried out in two different media like deionised water and simulated 
meal, in  order  to monitor  possible difference.  The results  showed  that higher 
molecular weight polymers with slower rate of hydration had 
enhanced floating behaviour and which was more in simulated meal medium compared 
to deionised water. 
Content uniformity, Hardness, Friability (Tablets):  
These tests are performed as per described in specified monographs. 
Resultant weight:    
The in vitro measuring apparatus has been conceived to determine the real 
floating capabilities of buoyant dosage forms as a function of time. It operates by force 
equivalent to the force F required to keep the object totally submerged in the fluid. This 
force determines the resultant weight of the object when immersed and may be used to 
quantify its floating or non floating capabilities. The magnitude and direction of the 
force and the resultant weight corresponds to the Victoria sum of buoyancy (Fbuoy) and 
gravity (Fgrav) forces acting on the objects as shown in the equal 
F = Fbuoy – Fgrav 
F = dfgV – dsgV = (df-ds) gv 
F = (df – M/V) gV 
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In which the F is total vertical force (resultant weight of the object), g is the 
acceleration due to gravity, df if the fluid density, ds is the object density is the object 
mass and V is the volume of the object.  
X-Ray/Gamma Scintigraphy:  
X-Ray/Gamma Scintigraphy is a very       popularly used evaluation parameter 
for floating dosage form these days. It helps to locate dosage form in the GIT and by 
which one can predict and correlate the gastric emptying time and the passage of 
dosage form in the GIT. Here the inclusion of a radio- opaque material into a solid 
dosage form enables it to be visualized by X-rays. Similarly, the inclusion of a γ-
emitting radio nucleide in a formulation allows indirect external observation using a γ-
camera or scinti scanner. 
Pharmacokinetic studies:  
Pharmacokinetic studies are the integral part of the in vivo studies. Sawicki et al 
studied the pharmacokinetics of Verapamil, from the floating pellets containing drug,  
filled  into a  capsule,  and  compared  with  the conventional Verapamil tablets of 
similar dose (40 mg). The tmax  and AUC (0-infinity)  values  (3.75  h  and  364.65  
ng.ml-1h  respectively)  for floating pellets were comparatively higher than those 
obtained for the  conventional  Verapamil  tablets.  (tmax   value1.21  h,  and  AUC 
value 224.22 ng.ml-1h). No much difference was found between the Cmax values of 
both the formulations, suggesting the improved bioavailability of the floating pellets 
compared to the conventional tablets. The microspheres showed about 1.4 times more 
bioavailability, and the elimination half-life was increased by about three times than the 
free drug. 
Specific Gravity:  
Specific Gravity of the floating system can be determined by   the displacement   
benzene as a displacing medium 
 
1.9. FUTURE POTENTIAL OF FDDS 
Floating dosage form offers various future potential as evident from several 
recent publications. Among the recently used clinical drugs several narrow absorption 
window drugs may benefit from compounding into a FDDS. Replacing parenteral 
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administration of drugs   to   oral   pharmacotherapy   would   substantially   improve 
treatment. It may be believed that it can be possible with FDDS. Drugs that have poor 
bio-availability because of their limited absorption to the upper gastrointestinal tract can 
be delivered efficiently into FDDS.  Thereby maximizing  their  absorption  and 
improving their absolute bioavailability. The floating concept can also be utilized in 
the development of various anti-reflux formulations. Developing a controlled release 
system for the drugs, which are potential to treat the Parkinson’s disease, is also an 
important  area  of  consideration.  Combination  therapy  to  treat H.pylori infection in a 
single FDDS needs to be developed. The study of the effect of various geometric 
shapes in a more excessive manner than previous studies on gastro retentivity needs to be 
developed. The investigations can be concentrated on the concept of design of novel 
polymers according to clinical and pharmaceutical need. 
 
 
 
Table 2: Polymers used for development of floating drug delivery 101 
Tablets Capsule Microsphere/ 
Microparticles 
 
Cellulosic hydrocolloids 
HPMC 
HPC 
HEC 
MC 
NaCMC 
 
Cellulosic 
hydrocolloids 
HPMC 
HPC 
HEC 
NaCMC 
 
Cellulose 
derivative 
Ethyl cellulose 
 
Gel-forming 
hydrocolloids and 
matrix former 
Carbopol 
Carrageenan 
Gum guar 
Gum Arabic 
Sodium alginate 
Polyethylene oxide 
Polyvinyl lactam 
Polyarcylates, 
Polyvinyl acetate 
Gel-forming 
hydrocolloids and 
matrix former 
Sodium alginate 
Carbopol 
Agar 
 
Gel-forming 
hydrocolloids and 
matrix former 
Eudragit 
Polycarbonate, 
Polyacrylate, 
Polymethacrylate 
Polystyrene 
Chitosan 
Gelatin 
Alginate 
Gelucir 
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Polymers used in floating drug delivery102 
1. Sustained Release Polymers are HPMC K100M, HPMC K15M, HPMC ELV, 
Polycarbonate, Polyethylene 
2. glycol, Sodium alginate, Carbopol, Eudragit. 
3. Effervescent Generating System: Citric acid, Tartaric Acid, Sodium Bicarbonate, 
Citroglycine. 
4. Polymers which increase buoyancy: Ethyl cellulose 
5. Polymers which decrease release: Talc, Magnesium Stearate, Dicalcium 
Phosphate. 
6. Polymers which increase release: Mannitol, Lactose. 
7. Inert Polymers: Long Chain Fatty Alcohol, Fatty Acid, Beeswax. 
8. Polymers with low density: Foam powder of polypropylene. 
 
 
 
Table 3: Commonly used drug in formulation of gastro retentive dosages forms 
Commonly used drug in formulation of gastro retentive dosages forms 103 
Dosage forms Drugs 
Floating Tablets 
 
Acetaminophen, Acetylsalicylic acid, Ampicillin, Amoxicillin 
trihydrate, 
Atenolol, Captopril, Cinnerzine, Chlorpheniramine maleate, 
Ciprofloxacin, Diltiazem, Fluorouracil, Isosorbide dinitrate, 
Isosorbid mononitrate, p- Aminobenzoic acid(PABA), 
Prednisolone, 
Nimodipine, Sotalol, Theophylline, Verapamil. 
Floating Capsules 
 
Chlordiazepoxide HCl, Diazepam, Furosemide, L-DOPA and 
Benserazide, Nicardipine, Misoprostol, Propranolol, Pepstatin 
Floating Microspheres 
 
Aspirin, Griseofulvin, p-nitro aniline, Ibuprofen, Terfenadine, 
Tranilast 
Floating Granules Diclofenac sodium, Indomethacin, Prednisolone 
Powders  Several Acidic drugs 
Films  Cinnerzine 
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2. LITERATURE REVIEW 
 Narasimharao et al., The oral route of administration of drugs is the most 
important method for achieving systemic effects. In the process of absorption of 
drug from oral route dissolution is the rate limiting step. Since the drug belongs to 
BCS class III, it is necessary to retard dissolution to ensure extended release of 
drug. Metformin hydrochloride is an anti diabetic, having an elimination half life 
of 5±2 hrs and its maximum daily dose is 1000mg. Hence it is an ideal candidate 
for extended release formulation. The objective of the study is to prepare 
metformin hydrochloride extended release tablets by direct compression 
technology using different polymer grades to achieve the desired dissolution 
pattern(21). 
 
 Kshirsagar et al., The objective of the present study was to develop a hydro 
dynamically balanced system of metformin as a single unit floating tablet. Various 
grades of low‐density polymers were used for the formulation of this system. 
They were prepared by physical blending of metformin and the polymers in 
varying ratios. The formulation was optimized on the in vitro buoyancy and in 
vitro release in simulated gastric fluid pH1.2. Effect of Carbopol as a release 
modifier was studied to ensure the delivery over a prolonged time period (23). 
 
 Eytan et al., Expandable gastroretentive dosage forms (GRDFs) have been 
designed for the past 3 decades. They were originally created for possible 
veterinary use, but later the design was modified for enhanced drug therapy in 
humans. These GRDFs are easily swallowed and reach a significantly larger size 
in the stomach due to swelling or unfolding processes that prolong their gastric 
retention time (GRT). After drug release, their dimensions are minimized with 
subsequent evacuation from the stomach. Gastroretentivity is enhanced by the 
combination of substantial dimensions with high rigidity of the dosage form to 
withstand the peristalsis and mechanical contractility of the stomach. Positive 
results were obtained in preclinical and clinical studies evaluating GRT of 
expandable GRDFs. Narrow absorption window drugs compounded in such 
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systems have improved in vivo absorption properties. These findings are an 
important step towards the implementation of expandable GRDFs in the clinical 
setting. (17). 
 
 Amit Kumar Nayak et al. proposed that the purpose of writing this review on 
gastroretentive drug delivery systems was to compile the recent literature with 
special focus on various gastroretentive approaches that have recently become 
leading methodologies in the field of site-specific orally administered controlled 
release drug delivery. In order to understand various physiological difficulties to 
achieve gastric retention, we have summarized important factors controlling 
gastric retention. Afterwards, we have reviewed various gastroretentive 
approaches designed and developed until now, i.e. high density (sinking), 
floating, bio- or mucoadhesive, expandable, unfold able, super porous hydrogel 
and magnetic systems. Finally, advantages of gastroretentive drug delivery 
systems were covered in detail (3). 
 
 R Garg et al., proposed that Controlled release (CR) dosage forms have been 
extensively used to improve therapy with several important drugs. However, the 
development processes are faced with several physiological difficulties such as 
the inability to restrain and localize the system within the desired region of the 
gastrointestinal tract and the highly variable nature of the gastric emptying 
process. This variability may lead to unpredictable bioavailability and times to 
achieve peak plasma levels. On the other hand, incorporation of the drug in a 
controlled release gastroretentive dosage forms (CR-GRDF) which can remain in 
the gastric region for several hours would significantly prolong the gastric 
residence time of drugs and improve bioavailability, reduce drug waste, and 
enhance the solubility of drugs that are less soluble in high pH environment. 
Gastroretention would also facilitate local drug delivery to the stomach and 
proximal small intestine. Thus, gastroretention could help to provide greater 
availability of new products and consequently improved therapeutic activity and 
substantial benefits to patients. Controlled gastric retention of solid dosage form 
may be achieved by the mechanisms of floatation, mucoadhesion, sedimentation, 
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expansion or by a modified shaped system. The purpose of this paper is to review 
the recent literature and current technology used in the development of 
gastroretentive dosage forms (1).  
 Vinod et al. proposed that much attention have been focused in pharmaceutical 
research in the area of gastroretensive oral drug delivery systems.  Henceforth a 
wide spectrum of dosage forms have been developed for drugs which are unstable 
in alkaline pH, soluble in acidic pH, having a narrow absorption window, site of 
action specific to stomach. This article provides the entire classification of 
gastroretensive systems, formulation considerations for developing 
gastroretensive systems, factors affecting gastroretensive systems, merits and 
demerits, applications in pharmacy and a comparative diagrammatic 
representation limelight this article.  Those gastroretensive systems which depend 
on liberation of carbondioxide show poor patient compliance because of 
flatulence and belching (2). 
 
 Nirav Rabadia  et al., proposed that floating drug delivery systems (FDDS) was 
to show that how this drug delivery system is best for calcium channel blocker and 
to compile the recent literature with special focus on the principal mechanism of 
floatation to achieve gastric retention. The recent developments of FDDS 
including the physiological and formulation variables affecting gastric retention, 
approaches to design single-unit and multiple-unit floating systems, and their 
classification and formulation aspects are covered in detail. This review also 
summarizes the invitro techniques, invivo studies to evaluate the performance and 
application of floating systems, and applications of these systems. These systems 
are useful to several problems encountered during the development of a 
pharmaceutical dosage form (5). 
 
 Vaishali Sharma et al. proposed that Success of oral drug delivery system 
depends on its degree of absorption through GIT. Thus, the idea of enhancing 
drug absorption in the GIT pioneered the idea of development of Gastroretentive 
drug delivery system. To design and evaluate the performance of GRDDS, it is 
important to understand the relevant anatomy and physiology of the GI tract. To 
CHAPTER-2                                                      LITERATURE REVIEW  
    
Dept. of Pharmaceutics                                       36                       J.K.K.Nattraja College of Pharmacy 
 
achieve gastric retention, the dosage form should satisfy certain requirements; 
primarily, the dosage form must be able to withstand the forceful peristaltic waves 
in the stomach and the constant contractions, grinding and churning. To function 
as a gastric retention device, it must resist premature gastric emptying. Once the 
purpose has been served, the device should be removed from the stomach with 
ease. Floating DDS or hydrodynamically balanced systems (HBS) have a bulk 
density lower than the gastric fluids (<~1.004 g/cm³), and thus remain buoyant in 
the stomach without affecting the gastric emptying rate for a prolonged period of 
time. Using FDDS one can easily increase the absorption of gastric secretion-
labile drugs (6). 
 
 Shukla Shruti et al., proposed that the purpose of writing this review on floating 
drug delivery systems (FDDS) was to compile the recent literature with special 
focus on the principal mechanism of floatation to achieve gastric retention. In 
recent years scientific and technological advancements have been made in the 
research and development of rate-controlled oral drug delivery systems by 
overcoming physiological adversities, such as short gastric residence times (GRT) 
and unpredictable gastric emptying times (GET). Systems which are retained in 
the stomach for a longer period of time and thereby improve the bioavailability of 
drugs. Several approaches are currently utilized in the prolongation of the GRT, 
including floating drug delivery systems (FDDS), also known as 
hydrodynamically balanced systems (HBS), swelling and expanding systems, 
polymeric bioadhesive systems, modified-shape systems, high-density systems, 
and other delayed gastric emptying devices. In this review, current & recent 
developments of Stomach Specific FDDS are discussed (11). 
 Natasha Sharma et al. proposed the concept behind the development of novel 
delivery system in certain drawback of conventional dosages form and to 
overcome the certain aspect related to physicochemical properties of drug 
molecule and related the formulation development. Controlled release floating 
drug delivery system is a promising delivery system for a drug candidate having 
limited absorption window sparingly soluble and insoluble drugs, drugs those 
locally release in stomach and shows degradability in colon or poor colonic 
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absorption. Floating drug delivery system comes under a gastroretentive drug 
delivery system that provides continuous controlled administration of sparingly 
soluble drugs at the absorption site. This review entitled the detailed scenario 
related to floating drug delivery system with their advantages over the 
conventional drug delivery system and also limitation, which are helpful in 
development of dosages form. Various types of techniques employed for 
development of this dosages form. Review focused on formulation aspect of 
effervescent floating drug delivery system with their evaluation techniques. The 
purpose of this comprehensive review is to compile the work going on this 
delivery system. Which provide the valuable information related to formulation 
aspect to achieve gastric retention and discussed the various factors affect and to 
overcome it (8).  
 Ravi P. Soni et al. proposed that in recent years several advancement has been 
made in research and development of oral drug delivery system.  The oral route 
achieved such popularity due to its ease of administration but has a drawback of 
non-site specificity. To overcome these limitations, gastric retentive drug delivery 
system is used. In order to understand various physiological difficulties to achieve 
gastric retention, we have summarized important factors controlling gastric 
retention time. We have reviewed various gastro retentive approaches designed 
and developed until now i.e. floating drug dosage systems (FDDS), swelling or 
expanding systems, mucoadhesive systems, high density system, Raft forming 
system, magnetic systems. Among these systems, FDDS have been most 
commonly used. Finally, Evaluation, advantages, disadvantages, future potential 
and marketed preparation of gastro retentive drug delivery systems were 
covered(7). 
 
 Santosh Shep et al., proposed that Swelling Drug delivery system are designed to 
prolong the gastric residence time after oral administration, at particular site and 
controlling the release of drug especially useful for achieving controlled plasma 
level as well as improving bioavailability. In recent year’s scientific and 
technological advancements have been made in the research and development of 
controlled release oral drug delivery systems by overcoming physiological 
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adversities like short gastric residence times and unpredictable gastric emptying 
times. Swelling drug delivery systems is the system which is retained in the 
stomach for a longer period of time and thereby improve the bioavailability of 
drugs. Swelling dosage systems form important technological drug delivery 
systems with gastric retentive behavior and offer several advantages in drug 
delivery. Treatment of gastrointestinal disorders such as gastro-esophageal reflux. 
Improved drug absorption, because of increased GRT and more time spent by the 
dosage form at its absorption site. Minimizing the mucosal irritation due to drugs, 
by drug releasing slowly at controlled rate (18).  
 
 Shah S.H et al., proposed that the technological attempts have been made in the 
research and development of rate-controlled oral drug delivery systems to 
overcome physiological adversities, such as short gastric residence times (GRT) 
and unpredictable gastric emptying times (GET). It is known that differences in 
gastric physiology, such as, gastric pH, and motility exhibit both intra-as well as 
inter-subject variability demonstrating significant impact on gastric retention time 
and drug delivery behavior. This triggered the attention towards formulation of 
stomach specific (gastro retentive) dosage forms. This dosage forms will be very 
much useful to deliver ‘narrow absorption window’ drugs. Several approaches are 
currently utilized in the prolongation of the GRT, including floating drug delivery 
systems (FDDS), swelling and expanding systems, polymeric bioadhesive 
systems, high-density systems, modified-shape systems and other delayed gastric 
emptying devices. In this review, current & recent developments of Stomach 
Specific FDDS are discussed (15). 
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3. AIM AND OBJECTIVE 
The aim of the present study is to formulate and evaluate gastro retentive 
tablet of famotidine for the treatment of peptic ulcer, thus the action would be 
specifically in the stomach. 
Famotidine is a histamine H2 receptor antagonist that inhibits stomach acid 
production. It is commonly used in the treatment of peptic ulcer disease (PUD) and 
gastroesophageal reflux disease (GERD). Famotidine is available in different dosage 
forms, like tablets, solutions and injections. The dose of 20mg, 40 mg is available. 
Half-life of famotidine is around 2.5 to 3.5 hr, therefore it is used for floating 
sustained release of the drug is possible. 
Dosage forms that can be retained in the stomach are called gastro retentive 
drug delivery system. GRDDS can improve the controlled delivery of drugs that have 
an absorption window by continuously releasing the drug for a prolonged period of 
time before it reaches its absorption site.  
Oral controlled release (CR) dosage forms (DFs) have been developed over 
the past three decades due to their considerable therapeutic advantages such as ease of 
administration, patient compliance and flexibility in formulation. However, this 
approach with several physiological difficulties such as inability to restrain and locate 
the controlled drug delivery system within the desired region of the gastrointestinal 
tract (GIT) due to variable gastric emptying and motility. Furthermore, the relatively 
brief gastric emptying time (GET) in humans which normally averages 2-3 h through 
the major absorption zone, i.e., stomach and upper part of the intestine can result in 
incomplete drug release from the drug delivery system leading to reduced efficacy of 
the administered dose. Therefore, control of placement of a drug delivery system 
(DDS) in a specific region of the GI tract offers advantages for a variety of important 
drugs characterized by a narrow absorption window in the GIT or drugs with a 
stability problem.  
These considerations have led to the development of a unique oral controlled 
release dosage form with gastroretentive properties. After oral administration, such a 
DF would be retained in the stomach and release the drug there in a controlled and 
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prolonged manner, so that the drug could be supplied continuously to its absorption 
sites in the upper gastrointestinal tract.  
Gastroretentive dosage form can remain in the gastric region for several hours and 
hence significantly prolong the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and improves solubility of 
drugs that are less soluble in a high pH environment. It is also suitable for local drug 
delivery to the stomach and proximal small intestines. 
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4. PLAN OF WORK 
1. Literature survey.  
2. Procurement of drug, polymer and other excipients. 
3. Preformulation studies: 
 Organoleptic properties 
 Flow properties 
 Bulk and tapped densities 
 Measurement of powder compressibility 
 Melting point 
 PH of the solution 
 Solubility 
 Drug-excipient compatibility 
 Preparation of standard curve 
4. Formulation of Famotidine tablets 
5. Pre-compression parameters 
 Angle of repose 
 Measurement of Bulk density and Tapped density 
 Measurement of Compressibility index and Hausner’s ratio 
6. Evaluation of Famotidine tablets 
 Evaluation of hardness  
 Thickness 
 Friability 
 Weight variation 
 Content uniformity 
 Buoyancy studies 
 In-vitro dissolution studies 
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5. DISEASE PROFILE - ULCER 
INTRODUCTION: 
Stomach ulcers, also known as gastric ulcers, are open sores that develop on the 
lining of the stomach. 
Ulcers can also occur in part of the intestine just beyond the stomach – these are known 
as duodenal ulcers. 
Both stomach and duodenal ulcers are sometimes referred to as peptic ulcers. 
Here the term “stomach ulcer” will be used, although the information applies equally to 
duodenal ulcers. 
Peptic ulcers include: 
• Gastric ulcers that occur on the inside of the stomach 
• Duodenal ulcers that occur on the inside of the upper portion of your small 
intestine (duodenum) 
Fig.no.14. Peptic ulcer 
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SIGNS AND SYMPTOMS: 
The most common symptom of a stomach ulcer is, 
• Burning stomach pain 
• Feeling of fullness, bloating or belching 
• Fatty food intolerance 
• Heartburn 
• Nausea 
The most common peptic ulcer symptom is burning stomach pain. Stomach acid 
makes the pain worse, as does having an empty stomach. The pain can often be relieved 
by eating certain foods that buffer stomach acid or by taking an acid-reducing 
medication, but then it may come back. The pain may be worse between meals and at 
night. 
Nearly three-quarters of people with peptic ulcers don't have symptoms. Less 
often, ulcers may cause severe signs or symptoms such as: 
• Vomiting or vomiting blood — which may appear red or black 
• Dark blood in stools, or stools that are black or tarry 
• Trouble breathing 
• Feeling faint 
• Nausea or vomiting 
• Unexplained weight loss 
• Appetite changes 
However, stomach ulcers aren't always painful and some people may experience 
other symptoms, such as indigestion, heartburn and feeling sick.   
 
CAUSES STOMACH ULCERS: 
Stomach ulcers occur when the layer that protects the stomach lining from 
stomach acid breaks down, which allows the stomach lining to become damaged. 
This is usually a result of : 
a) H. pylori bacteria 
H. pylori infections are common, and it's possible to be infected without realising 
it, because the infection doesn't usually cause symptoms. The bacteria live in the stomach 
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lining and people of all ages can be infected. However, in some people, the bacteria can 
irritate the stomach lining and make it more vulnerable to damage from the stomach acid.  
b) NSAIDs 
NSAIDs are medicines widely used to treat pain, a high temperature (fever) and 
inflammation (swelling). 
Commonly used NSAIDs include: 
• ibuprofen 
• aspirin 
• naproxen 
• diclofenac 
Many people take NSAIDs without having any side effects, but there's always a 
risk the medication could cause problems, such as stomach ulcers, particularly if taken 
for a long time or at high doses. 
NSAIDs not to be used the person having a stomach ulcer. Paracetamol can often 
be used as an alternative painkiller, as it's generally considered safer. 
c) Lifestyle factors 
It used to be thought that stomach ulcers may be caused by certain lifestyle factors, such 
as spicy foods, stress and alcohol. 
There is little hard evidence to confirm that this is the case, but these factors may make 
the symptoms of ulcers worse. 
However, it is thought that smoking increases your risk of developing stomach ulcers and 
may make treatment less effective. 
 
DIAGNOSIS:  
The patient have an ulcer which will be identified, based on the symptoms. They 
will want to know if they are taking non-steroidal anti-inflammatory drugs (NSAIDs)and 
may test for an Helicobacter pylori (H. pylori) infection. 
Next test is to perform a gastroscopy. 
a) Testing for H. pylori infection 
The symptoms may be caused by an H. pylori infection, they may recommend one of 
the following tests: 
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• urea breath test – you will be given a special drink containing a chemical that 
is broken down by H. pylori; your breath is then analysed to see whether or not 
you have an H. pylori infection 
• stool antigen test – a small stool sample is tested for the bacteria 
• blood test – a sample of your blood is tested for antibodies to the H. pylori 
bacteria (antibodies are proteins produced naturally in your blood and help to 
fight infection); this has now largely been replaced by the stool antigen test 
If test positive for H. pylori, you will need treatment to clear the infection, which can heal 
the ulcer and prevent it from returning.  
b) Gastroscopy 
The procedure is carried out in hospital and involves passing a thin, flexible tube 
(an endoscope) with a camera at one end into your mouth and down into your stomach 
and first section of the small intestine (duodenum). 
The images taken by the camera will usually confirm or rule out an ulcer. A small tissue 
sample may also be taken from your stomach or duodenum, so it can be tested for the H. 
pylori bacteria. 
 
TREATEMENT: 
• With treatment, most stomach ulcers will heal within a month or two. The 
treatment recommended for you will depend on what caused the ulcer. 
• Most people will be prescribed a medication called a proton pump 
inhibitor (PPI) to reduce the amount of acid their stomach produces, 
and allow the ulcer to heal naturally. 
• If an H. pylori infection is responsible for the ulcers, antibiotics will 
also be used to kill the bacteria, which should prevent the ulcer coming 
back. 
• If the ulcers are caused by the use of NSAIDs,  Alternative medication to 
NSAIDs, such as paracetamol, may be recommended. 
• Stomach ulcers can come back after treatment, although this is less likely 
to happen if the underlying cause is addressed. 
• An alternative type of medication, known as H2-receptor antagonists, is 
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occasionally used instead of PPIs, and sometimes you may be given 
additional medication called antacids to relieve your symptoms in the 
short term. 
• They may have a repeat gastroscopy after 4 to 6 weeks to check that the 
ulcer has healed. 
• With certain special lifestyle measures to take during treatment, but 
avoiding stress, alcohol, spicy foods and smoking may reduce the 
symptoms while ulcer heals. 
• Some antacids also contain a medicine called an alginate, which produces 
a protective coating on the lining of the stomach. 
Complications 
Complications of stomach ulcers are relatively uncommon, but they can be very 
serious if they do occur. Some of the main complications are outlined below,  
a)Internal bleeding 
Internal bleeding is the most common complication of stomach ulcers. It can occur when 
an ulcer develops at the site of a blood vessel. 
b) Perforation 
A rarer complication of stomach ulcers is the lining of the stomach splitting open, known 
as perforation. 
c) Gastric outlet obstruction 
In some cases, an inflamed (swollen) or scarred stomach ulcer can obstruct the normal 
passage of food through your digestive system. This is known as gastric outlet 
obstruction. 
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Classification of anti-ulcer drugs 
1. Reduction of gastric acid secretion: 
a) H2 antihistaminics  
Cimetidine, Ranitidine, FAMOTIDINE, Roxatidine, Loxatidine etc 
b) Proton Pump Inhibitors  
Omeprazole, Lansoprazole, Pantoprazole, Rabeprazole, esomeprazole etc 
c) Anti-cholinergics  
Pirenzepine, Propantheline, Oxyphenonium etc 
d) Prostaglandin analogues  
Misoprostil, Enprostil, Rioprostil etc 
2. Neutralisation of gastric acid: 
Antacids are used for neutralising the gastric acid in the stomach. These drugs are 
known as antacids. 
a) Systemic antacids  
sodium bicarbonate (NaHCO3), sodium citrate etc 
b) Non systemic antacids  
Magnesium hydroxide (Mg(OH)2), Magnesium trisilicate, Alminium 
hydroxide gel, Calcium carbonate (CaCO3) etc 
3. Ulcer protectives: 
Ulcer protectives protect the ulcers by covering them and they consist of mainly 
polymers. 
Sucralfate, Colloidal Bismuth subcitrate (CBS) etc 
4. Ulcer Healing Drugs: 
Carbenoxolone sodium 
5. Anti H-Pylori drugs: 
Ulcer is also caused due to the action of the bacterium Helicobacter Pylori, so for 
treating the ulcers caused by the bacterium, anti biotics are given. 
Amoxicillin, Tinidazole, Tetracycline, Metronidazole, Clarithromycin 
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6. DRUG PROFILE 
FAMOTIDINE 
Famotidine, is a histamine H2 receptor antagonist that inhibits stomach acid production. 
It is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux 
disease.  
Generic Name: Famotidine  
Chemical Name: 3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)  
                  sulfanyl]-N'-sulfamoylpropanimidamide 
Empirical Formula: C8H15N7O2S3 
Physical and Chemical Properties 
Molecular weight - 337.449 g/mol,  
Color – White to pale yellow crystals,  
Nature -Crystalline powder,  
Odour- Odourless,  
Melting point- 163.5 °C,  
Solubility- Freely soluble in glacial acetic acid, slightly soluble in methanol, very 
slightly soluble in water, and practically insoluble in ethanol.  
pKa - 12.4. 
 
Pharmacokinetics: The bioavailability of oral doses is 40-45%. The apparent volume of 
distribution of the drug is reported to be 1.1-1.4 l/kg in adults and does not appear to be 
altered substantially in patients with renal dysfunction. Following oral or IV 
administration in rats, famotidine is widely distributed, appearing in highest 
concentrations in the kidney, liver, pancreas, and submandibular gland. The drug is 15-
20% protein bound. Renal clearance is 250-450 mL/min, indicating some tubular 
excretion. Clearance is renal cl=250-450 mL/min.  
 
Indications and Dosage:  
For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux 
disease (GERD). 
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Dosage Oral:  
40 mg orally once a day at bedtime OR 20 mg orally 2 times a day 
Maintenance dose: 20 mg orally once a day at bedtime. Duration of therapy: 4 
weeks 
Dosage  Parenteral: 
-Usual dose: 20 mg IV every 12 hours 
Overdose: 
Doses of up to 640 mg/day have been given to adult patients with pathological 
hypersecretory conditions with no serious adverse effects. In the event of overdosage, 
treatment should be symptomatic and supportive. Unabsorbed material should be 
removed from the gastrointestinal tract, the patient should be monitored, and supportive 
therapy should be employed. 
Contraindications: 
Hypersensitivity to any component of these products. Cross sensitivity in this 
class of compounds has been observed. Therefore, PEPCID should not be administered to 
patients with a history of hypersensitivity to other H2-receptor antagonists. 
Mechanism of Action: 
Famotidine binds competitively to H2-receptors located on the basolateral 
membrane of the parietal cell, blocking histamine affects. This competitive inhibition 
results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric 
volume, acidity, and amount of gastric acid released in response to stimuli including 
food, caffeine, insulin, betazole, or pentagastrin. 
Drug Interactions: Some interacting drugs  include atazanavir, dasatinib, delavirdine, 
certain azole antifungals (such as itraconazole, ketoconazole), pazopanib, among others. 
Food Interactions: Avoid alcohol, Limit caffeine intake, Take without regard to meals, 
food may slightly increase the product's bioavailability. 
Adverse Effects: 
Adverse nervous system effects (eg, headache, dizziness) and GI effects (eg, 
constipation, diarrhea) occur most frequently during famotidine therapy. Although 
adverse effects of the drug generally are not severe, discontinuance of famotidine therapy 
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has been necessary in up to 14% of patients. Adverse effects generally are similar when 
famotidine is administered orally or IV. 
Side Effects: 
Some rare side may include, Headache, Upper respiratory tract infection, 
Vomiting, Nausea, Diarrhoea, Influenza like illness, Dizziness, Back pain, Constipation, 
Rash, Abdominal pain 
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7. EXCIPIENTS DATA 
7.1 HYDROXYPROPYL METHYLCELLULOSE: 
Nonpropritary names: 
 Hypromellose (BP), methylhydroxypropylcellulosum (EUR), hydroxypropyl 
methylcellulose (USP). 
Synonym: 
 Cellulose,hydroxylpropyl methyl ester, culminalMHPC, E464,HPMC, 
Methocel, methocel, methylcellulose propylene glycol ether, methyl 
hydroxylpropylcellulose, metalose, pharmacoat. 
Chemical Name and CAS Registry Number 
Cellulose, 2-hydroxy propyl methyl ether, [9004-65-3] 
Emprical Formula and molecular weight:  
 Hydroxypropyl methylcellulose is a partly as a O-methylated andnO-(2 
hydroxylated) cellulose. Molecular weight varies from 10000 – 15000000. 
Description: 
 Hydroxypropyl methylcellulose is an odourless and tasteless, white or 
creamy-white coloured fibrous or granular powder. 
 
Solubility: 
Soluble in cold water, forming viscous colloidal solution. Practically insoluble 
in chloroform, ethanol (95%) and ether, but soluble in mixtures of ethanol and 
dichloromethane and mixtures of ethanol and dichloromethane  
Structural formula:  
 
Where R is H,CH3 or[CH3 CH(OH) CH2 ] 
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Moisture content:   
 Hydroxypropyl methylcellulose absorbs moisture content from the 
atmosphere. The amount of moisture depends upon the initial moisture content, 
temperature and relative humidity on the surrounding air. 
Viscosity content : 5-1000000 mPas (2%w/w solution at 20oC).  
The different commercial grades are available according to the viscosities, 
Methocel K4M             4000 mPas 
Methocel K15M 15000 mPas 
Methocel K100M 100000 mPas 
 
Density  : Density (bulk) 0.341 g/cm3. 
  Density (tapped) 0.557 g/cm3. 
  Density (true) 1.326 g/cm3. 
pH    : 5.5-8.9.(1%w/w aqueous solution at 25o). 
Melting point  : Browns at 190-2000C, Chars at 225-2300C. 
Loss on drying : ≤5.0% 
Burnt Residue : ≥1.0% 
Specific gravity : 1.26.  
Functional Category: 
 Coating agent, flim-former, stabilizing agent, suspending agent, tablet binder, 
vicosity increasing agent. 
Applications in Pharmaaceutical formulation or technology: 
 Hydroxypropyl methylcellulose is widely used in oral and topical 
pharmaceutical formulations. 
In Oral products, Hydroxypropyl methylcellulose is primarily used as a tablet 
binder, in flim-coating and as an extended release tablet matrix. Concentrations of 
between 2-5% w/w may be used as a binder.  
Hydroxypropyl methylcellulose is used as a suspending and thickening agent 
in topical formulation (opthalmic preparation). It gives greater clarity compared to 
methyl cellulose so it is preferred in opthalamic formulation in conc. of 0.45-1.0% 
w/w used. 
Hydroxypropyl methylcellulose is also used as an emulsifier, suspending 
CHAPTER-7                                                                                               EXCIPIENTS PROFILE  
   
Dept. of Pharmaceutics                                  53                    J.K.K.Nattraja College of Pharmacy 
 
agent and stabilizing agent in topical gels and ointments. 
In addition Hydroxypropyl methylcellulose is also used as an adhesive in 
plastic bandages. 
Incompatabilities: 
 Hydroxypropyl methylcellulose is incompatible with some oxidizing agents. 
Since it is nonionic, hydroxypropyl methylcellulose will not complex with metallic 
salts and organics to form insoluble precipitates. 
Stability and storage conditions: 
 It is stable although it is slightly hygroscopic. The bulk material should be 
stored in air tight container in a cool and dry place. 
 Safety: 
 It is widely used in many oral and topical pharmaaceutical formualtions. It is 
generally regarded as an essentially Non-toxic and Non-irritant material although 
excessive consumption may have laxative effect. 
 
7.2 WHITE BEES WAX 
Nonproprietary names: 
 White Beeswax (BP), Beeswax, White (PhEur), White Wax (USP-NF). 
Synonym: 
Bleached wax; cera alba. 
Chemical Name and CAS Registry Number 
 
Bleached wax; cera alba; E901, [8012-89-3] 
Emprical Formula and molecular weight:  
 Beeswax consists of 70–75% of a mixture of various esters of straight-chain 
monohydric alcohols with even-numbered carbon chains from C24 to C36 esterified 
with straight-chain acids. These straight-chain acids also have even numbers of 
carbon atoms up to C36 together with some C18 hydroxy acids. The chief ester is 
myricyl palmitate. Also present are free acids (about 14%) and carbohydrates (about 
12%) as well as approximately 1% free wax alcohols and stearic esters of fatty acids. 
Description: 
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Tasteless, white or slightly yellow-colored sheets or fine granules with some 
translucence. Its odour is less intense.  
 
Density : 0.95–0.96 g/cm3. 
 
Melting point: 61–650C. 
 
Solubility  
Soluble in chloroform, ether, fixed oils, volatile oils, and warm carbon 
disulfide, sparingly soluble in ethanol (95%), practically insoluble in water. 
Functional Category 
Controlled-release agent, stabilizing agent, stiffening agent. 
Incompatibilities 
Incompatible with oxidizing agents. 
Safety 
White wax is used in both topical and oral formulations, and is generally 
regarded as an essentially nontoxic and nonirritant material. However, although rare, 
hypersensitivity reactions to beeswax have been reported. 
 
Stability and Storage Conditions 
When the wax is heated above 1500C, esterification occurs with a consequent 
lowering of acid value and elevation of melting point. White wax is stable when 
stored in a well-closed container, protected from light. 
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7.3 SODIUM BICARBONATE 
Nonpropritary names: 
 Sodium Bicarbonate (BP, USP), Sodium Hydrogen Carbonate (PhEUR). 
Synonym: 
 Baking soda, E500, Effer-Soda, monosodium carbonate, sodium acid 
carbonate, sodium hydrogen carbonate. 
 
Chemical Name and CAS Registry Number: 
Carbonic acid monosodium salt, [144-55-8]. 
Emprical Formula and molecular weight:  
Formula: NaHCO3 MW: 84.01. 
Description: 
Sodium bicarbonate is an odorless, white, crystalline powder with a saline, 
slightly alkaline taste. The crystal structure is monoclinic prisms.  
pH   : 7.9-8.4. (5%w/w aqueous solution). 
Solubility  : Soluble in water in 1 in 11 ratio & insoluble in Ethanol and 
ether.  
Moisture content :   Sodium bicarbonate Moisture content less than 1%w/w. 
Melting point  : 2700 C (With decomposition). 
Functional Category : Alkalizing agent; therapeutic agent. 
Applications in Pharmaaceutical formulation or technology: 
 Sodium bicarbonate is generally used in effervescent tablets and Granules is 
formulated with citric and/or tartaric acid. When the tablets or granules come into 
contact with water, a chemical reaction occurs, carbon dioxide is evolved. Sodium 
bicarbonate is also used in tablet formulations to buffer drug molecules that are weak 
acids, thereby increasing the rate of tablet dissolution and reducing gastric irritation. 
Sodium bicarbonate has also been used as a freeze-drying stabilizer and increase 
absorption of some drugs. It is used in oral rehydration salts and also in dialysis 
fluids. 
Incompatabilities: 
Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, 
with the evolution of carbon dioxide.  
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Stability and storage conditions: 
Sodium bicarbonate is stable in dry air but slowly decomposes in moist air and 
should therefore be stored in a well-closed container in a cool, dry place.   
Safety:  
When used as an excipient, sodium bicarbonate is generally regarded as an 
essentially nontoxic and nonirritant material. Excessive amounts of sodium 
bicarbonate disturb the body’s electrolyte balance and orally ingested sodium 
bicarbonate neutralizes gastric acid may cause stomach cramps and flatulence. 
 
7.4 MAGNESIUM STEARATE 
Nonpropritary names: 
 Magnesium Stearate (BP, USP-NF, PhEUR). 
Synonym: 
 Dibasic magnesium stearate, magnesium distearate, magnesium 
octadecanoate, octadecanoic acid, magnesium salt, stearic acid. 
Chemical Name and CAS Registry Number :  
Octadecanoic acid magnesium salt, [557-04-0].  
Emprical Formula and molecular weight:  
Formula: C36H70MgO4. MW: 591.24. Structural formula: 
[CH3(CH2)16COO]2Mg. 
Description: 
Magnesium stearate is a very fine, light white, precipitated or milled, poorely 
flowing, cohesive powder, impalpable powder of low bulk density, having a faint 
odor of stearic acid and a characteristic taste. The powder is greasy to the touch and 
readily adheres to the skin. 
Solubility: 
Practically insoluble in ethanol, ether and water, slightly soluble in warm 
benzene and warm ethanol (95%).  
Melting point  : 117–1500C. 
Functional Category: Tablet and capsule lubricant. 
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Applications in Pharmaaceutical formulation or technology: 
 Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.  
 
Incompatabilities: 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salts.  
 
Stability and storage conditions: 
Magnesium stearate is stable and should be stored in a well-closed container 
in a cool, dry place.  
Safety:  
Magnesium stearate  is non-toxic for oral administration and larger 
consumption may result in laxative effect and mucosal irritation.  
 
7.5 TALC 
Nonpropritary names: 
 Purified Talc (BP), Talc (USP, PhEUR). 
Synonym: 
 Altalc, hydrous magnesium calcium silicate, hydrous magnesium silicate, 
Imperial, magnesium hydrogen metasilicate, powdered talc, purified French chalk, 
Purtalc, talcum. 
Emprical Formula and CAS Registry Number:  
 Mg6(Si2O5)4(OH)4, [14807-96-6] 
Description: 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Solubility: 
Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
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Moisture content:   
 Talc absorbs insignificant amounts of water at 250C and at a relative humidity 
of 75%. 
Functional Category: 
 Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Applications in Pharmaaceutical formulation or technology: 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent, it is also widely used as a dissolution retardant. In topical preparations, talc is 
used as a dusting powder. Talc is additionally used to clarify liquids and is also used 
in cosmetics and food products, mainly for its lubricant properties. Concentrations 
used asDusting powder 90.0–99.0, Glidant and tablet lubricant 1.0–10.0, Tablet and 
capsule diluent 5.0–30.0. 
 
Incompatabilities: 
Incompatible with quaternary ammonium compounds. 
Stability and storage conditions: 
 Talc is a stable material and may be sterilized by heating at 1600C for not less 
than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should be stored in a well-closed container in a cool, dry place.  
 
Safety: 
 Talc is used mainly in tablet and capsule formulations. Talc is not absorbed 
systemically following oral ingestion and is therefore regarded as an essentially 
nontoxic material. Talc contaminated with asbestos has been proved to be 
carcinogenic in humans, and asbestos-free grades should therefore be used in 
pharmaceutical products. 
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7.6 LACTOSE 
Nonpropritary names: 
 Lactose (BP), Lactose Monohydrate (PhEUR, USP-NF). 
Synonym: 
 CapsuLac, GranuLac, Lactochem, lactosum monohydricum, onohydrate, 
Pharmatose, PrismaLac, SacheLac, SorboLac, pheroLac, SuperTab 30GR, Tablettose. 
Chemical Name and CAS Registry Number: 
O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose monohydrate, [10039-26-
6] 
Emprical Formula and molecular weight:  
 Formula:C12H22O11·H2O.  MW: 360.31 
Description: 
In solid state, lactose appears as various isomeric forms, depending on the 
crystallization and drying conditions, i.e. αlactose monohydrate, β-lactose anhydrous, 
and α-lactose anhydrous. Lactose occurs as white to off-white crystalline particles or 
powder, it is odorless and slightly sweet-tasting. 
Structural formula:  
 
pH   :5.5-8.9.(1%w/w aqueous solution at 25o) 
Solubility : Insoluble in chloroform, ethanol, ether. Soluble in water in ratio of 1 
in            5.24. 
Melting point:  201–2020C (for dehydrated a-lactose monohydrate) 
 Moisture content:    
Lactose monohydrate contains normally has a range of 4.5–5.5% w/w water 
content. 
Functional Category: 
 Dry powder inhaler carrier, lyophilization aid, tablet binder, tablet and capsule 
diluent, tablet and capsule filler. 
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Applications in Pharmaaceutical formulation or technology: 
 Lactose is widely used as a filler and diluent in tablets and capsules. Lactose 
is also used as a diluent in dry-powder inhalation. Lactose is added to freeze-dried 
solutions to increase plug size and aid cohesion. Lactose is also used in combination 
with sucrose to prepare sugar-coating solutions. It may also be used in intravenous 
injections. Lactose is also used in the manufacture of dry powder formulations for use 
as aqueous film-coating solutions or suspensions. Direct-compression grades of 
lactose monohydrate are available as spray-dried lactose and anhydrous lactose. 
Incompatabilities: 
 A Maillard-type condensation reaction is likely to occur between lactose and 
compounds with a primary amine group to form brown, or yellow-brown-colored 
products. Lactose is also incompatible with amino acids, amphetamines and lisinopril. 
 
Stability and storage conditions: 
 Mold growth may occur under humid conditions (80% relative humidity and 
above). Lactose may develop a brown coloration on storage, the reaction being 
accelerated by warm, damp conditions. Solutions show mutarotation. Lactose should 
be stored in a well-closed container in a cool, dry place. 
 
Safety: 
 Lactose is widely used as a filler and filler-binder in orals and injections. 
Adverse reactions to lactose are largely attributed to lactose intolerance, results in 
lactose being undigested and may lead to cramps, diarrhea, distension, and flatulence.  
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8. MATERIALS AND EQUIPMENTS USED 
8.1. MATERIALS USED: 
 Table no. 4. List of materials used 
S.NO. MATERIALS SUPPLIER 
1. Famotidine Molecules India Pvt.Ltd. 
2. HPMC K4M Sooriyan pharmaceuticals., chennai 
3. HPMC K15M Sooriyan pharmaceuticals., chennai 
4. HPMC K100M Sooriyan pharmaceuticals., chennai 
5. Bees wax Fine Chem, industries. 
6. Sodium bicarbonate Fine Chem, industries. 
7. Lactose(monohydrate) Standard chemicals 
8. Magnesium stearate Advance labs 
9. Talc Fine Chem, industries. 
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8.2. INSTRUMENTS USED: 
Table no. 5. List of instruments used 
S.No. INSTRUMENTS MANUFACTURER 
1 Electronic balance  
Shimadzu Corporation, AW220 
&BX6205 
2 FTIR spectrophotometer Shimadzu Co UV-1700 
3 UV/Visible spectrophotometer Lab India UV 3000 
4 Dissolution Apparatus(USP) Electro lab Pvt. Ltd. 
5 Tablet Hardness tester Monsanto Hardness tester 
6 Friability test apparatus Roche Fribilator 
7 Tap Density Apparatus Erweka Pvt.Ltd 
8 PHmeter Systonic 335 
9 Tablet compression machine Proton Multipress 
10 Vernier Caplier Digimatic 
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9. PREFORMULATION 
Preformulation studies are carried out in order to evaluate the physical and 
chemical properties of the drug alone and in the combined form with the excipients. 
These studies are important to predict the physical and chemical properties 
and stability of the drug and excipients. 
 
9.1. ORGANOLEPTIC PROPERTIES: 
1. Colour: 
           Take a small quantity of sample and spread it on the white paper and examine 
it visually. 
9.2. PHYSICAL PROPERTIES: 
1. Angle of repose 
The flow characteristics are measured by angle of repose. Improper flow of 
powder is due to frictional forces between the particles. These frictional forces are 
quantified by angle of repose. 
Angle of repose is defined as the maximum angle possible between the 
surface of a file of the powder and the horizontal plan.           
Ø = Tan -1 h/r 
Where, h = height of file 
 R = radius of the base of the pile 
 Ø = angle of repose 
Flow properties and corresponding Angle of Repose 
Table No: 6. Flow properties and corresponding Angle of Repose 
Flow property Angle of Repose (Degree) 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable- may hang up 41-45 
Poor- must agitate, vibrate 46-55 
Very poor 56-65 
Very, very poor > 66 
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The ideal characteristics of a tablet that make it a popular and acceptable 
dosage form are compactness, physical stability, rapid production capability, chemical 
stability and efficacy. In general above characteristics of tablet are dictated by the 
quality of the granulation from which it is made. Many formulation and process 
variables involved in the granulation step can affect the characteristics of the 
granulation produced. Therefore various methods to measure certain granulation 
characteristics have been developed to monitor granulation suitability for tablet 
formulation. The main characteristics required to be monitored in granulation are 
flow properties and compressibility. 
 
2. Determinations of bulk density and tapped density: 
An accurately weighed quantity of the powder (w) was carefully poured into 
the graduated cylinder and the volume (v0) was measured. Then  the graduated 
cylinder was closed with lid, set into the density determination apparatus (Bulk 
density apparatus) the density apparatus was set for 500 taps and after that, the 
volume (vf) was measured and continued operation till the two consecutive readings 
were equal. 
The bulk density and tapped density were calculated using the following 
formulas. 
Bulk Density     = W/V0 
Tapped Density = W/Vf 
Where, V0= Initial volume, 
Vf = final volume 
 
3. Compressibility index 
The compressibility Index and Hausner ratio are measures of the property of a 
powder to be compressed. As such, they measure the relative importance of 
interparticulate interactions. In a free flowing powder, such interactions are generally 
less significant, and the bulk and tapped densities will be closer in value. For poorer 
flowing materials, there are frequently greater inter particle interactions, and a greater 
difference between the bulk and tapped densities will be observed. These differences 
are reflected in the compressibility index and the Hausner ratio. 
CHAPTER-9                                                                                                PREFORMULATION  
   
Dept. of Pharmaceutics                                64                       J.K.K.Nattraja College of Pharmacy 
 
The compressibility index and hausner ratio are calculated by measuring the 
values for bulk density (P bulk) and tapped density (P tapped) as follows: 
Compressibility index =        P tapped – P bulk/P tappedX 100 
 
Hausner ratio   = P tapped / P bulk
 
 
Scale of flowability 
Table No: 7. Scale of flowability 
Compressibility index (%) Flow character Hausner Ratio 
≤ 10 Excellent 1.10-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very, very poor >1.60 
 
4. Melting point: 
It is the characteristic to test the purity of the sample. 
Procedure: 
Take a small quantity of sample into the fusion tube. Place the tube in the 
mating point apparatus containing castor oil. Increase the temperature of castor oil 
gradually and note the temperature starts to melt and when all the powder completely 
melts. 
 
9.3. Solubility: 
Take a small quantity of sample and add the solvent until the sample 
completely dissolves. It is examined visually for the presence of any un dissolved 
particles. 
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9.4.Drug-excipient compatibility studies: 
 Drug-excipient compatibility studies are important to know the interaction 
between drug and excipients and in between excipients of the formulation, which 
could later affect the stability of the formulation and may interfere with the 
pharmacological action of the drug. 
  
The physical examination of the formulation is done when alone and in 
combination with the excipients. If there is any change in the physical appearance, 
shows that there is interaction. 
 But some substances do not show any physical changes when combined in a 
formulation, for such FT-IR (Fourier transform-infrared) studies are conducted. 
 
Procedure by FT-IR studies: 
The FT-IR studies are conducted for Famotidine and mixture of famotidine 
and excipients by preparing dispersion in potassium bromide discs. The peaks are 
obtained and compared with the standards by superimposing these spectra and 
observed for any difference in shape and size of spectrum. If there is any significant 
change represents interaction between drug and excipients.  
 
9.5.PREPARATION OF STANDARD CURVE 
Preparation of 0.1 M Hydrochloric acid: 
Accurately measure 8.5 ml of hydrochloric acid and sufficient water to make 
upto 1000 ml. 
Preparation of stock solution: 
Accurately weigh 100 mg of Famotidine and transfer it to a 100 ml volumetric 
flask. Then make up the volume to 100 ml with 0.1 M Hcl. 
Preparation of standard solution: 
Pipette out 10 ml of the above solution and transfer it to a 100 ml volumetric 
flask. Then make up the volume to 100 ml with 0.1 M Hcl. Then from the standard 
stock solution withdraw 2ml, 4ml, 6ml, 8ml, and 10ml into five 100 ml different 
volumetric flasks. Then make up the volume to 100 ml with 0.1M Hcl to get 2, 4, 6, 
8, 10 µg/ml concentration.  
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CALIBRATION CURVE OF FAMOTIDINE: 
The absorbance of the prepared stock solutions was measured at 266 nm in an 
UV spectrophotometer. Plot a graph between concentration (in µg/ml) vs absorbance 
(in nm) on X-axis and Y-axis respectively. 
 
Table no. 8. Calibration curve of Famotidine 
 
 
 
 
Fig.no.15 .Calibration curve of Famotidine 
 
 
S.no. Concentration(in µg/ml) Absorbance  (in nm) 
1. 0 0.000 
2. 5 0.123 
3. 10 0.233 
4. 15 0.369 
5. 20 0.497 
6. 25 0.621 
Slope 0.0247  
R2 0.9992  
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10. FORMULATION AND DEVELOPMENT OF FAMOTIDINE 
TABLETS 
Table.no.9: Formulation of Famotidine tablets 
 
INGREDIENTS(in 
mg) 
FORMULATION BATCHES 
F1 F2 F3 F4 F5 F6 F7 F8 
Famotidine 40 40 40 40 40 40 40 40 
HPMC K4M 0 30 0 0 30 30 0 30 
HPMC K15M 0 0 30 0 30 0 30 30 
HPMC K100M 0 0 0 30 0 30 30 30 
NaHCO3 20 20 20 20 20 20 20 20 
Bees wax 30 30 30 30 30 30 30 30 
Lactose 98 68 68 68 38 38 38 8 
Magnesium sterate 6 6 6 6 6 6 6 6 
Talc 6 6 6 6 6 6 6 6 
Average weight 200 200 200 200 200 200 200 200 
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10.1 STEPS INVOLVED IN FORMULATION: 
a) Sieving: 
  The ingredients were accurately weighed. Famotidine was sieved from 
mesh no. 80 then, HPMC K4, HPMC K15, HPMC K100, Sieved through 
mesh no. 80. 
b) Melting: 
  White bees wax was melted in a chinadish. 
c) Mixing: 
            Add Famotidine drug on molten mass and stirred well to mix. Then 
add HPMC polymer, sodium bicarbonate and lactose and mix it well.  
d) Granulation: 
            Then the mass was allowed to cool to room temperature and then 
scrapped from chinadish. The coherent mass was passed through sieve no. 20.  
e) Lubrication: 
  The resulting granules were mixed with magnesium stearate and talc. 
f) Compression: 
  The lubricated granules were compressed into tablets using standard 
concave punch with 10 station rotary Proton mini press machine and keeping 
average weight of 200 mg.  
After compression weight variation, Friability, dissolution and assay 
test were carried out. 
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11. EVALUATION 
11.1. Pre-compression parameters: 
1. Angle of repose: 
Take a small quantity of powder(5 gm) in a cone shaped funnel and fix it to a 
holder at an appropriate height say 6 cm above the surface. Place a graph sheet below it. 
The sample was passed slowly through the funnel. The height of the powder heap was 
formed. Then measure the circumference of the heap by drawing with the pencil on the 
graph sheet. The radius of the heap was measured. The angle of repose is calculated by 
using the following formula. This is repeated five times for accurate results. 
Ø = Tan -1 h/r  
      Where,      h = height of file 
R= radius of the base of the pile 
Ø = angle of repose 
The results were tabulated in table. 
 
2.Bulk density and Tapped density: 
Weigh a small quantity of the powder (w) was carefully poured into the graduated 
cylinder and the volume (v0) was measured. Then the graduated cylinder was closed with 
lid, set into the density determination apparatus (Bulk density apparatus) set for 500 taps 
and after that, the volume (vf) was measured and continued operation till the two 
consecutive readings were equal. 
The bulk density and tapped density were calculated using the following 
formulas. 
Bulk Density     = W/V0 
Tapped Density = W/Vf 
Where, V0= Initial volume, 
Vf = final volume 
The results were tabulated in table. 
 
3. Compressibility index and Hausner ratio: 
The compressibility index and hausner ratio are calculated by measuring the 
values for bulk density (P bulk) and tapped density (P tapped) as follows: 
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Compressibility index =     P tapped – P bulk/P tappedX 100 
                                     Hausner ratio   = P tapped / P bulk 
The results were tabulated in table. 
 
11.2. EVALUATION OF FORMULATED TABLETS OF FAMOTIDINE20 
All the formulated sustained release tablets were evaluated for following official 
and unofficial parameters. 
1. Weight Variation 
Twenty tablets were randomly selected from each batch and individually weighed. 
The average weight and standard deviation of twenty tablets was calculated. The batch 
passes the test for weight variation test if not more than two of the individual tablet 
weight deviate from the average weight by more than the percentage shown in a none 
deviate by more than twice the percentage shown. 
% deviation= tablet weight-average weight x 100 
Tablet weight 
Observation: 
The average weight and standard deviation of the tablets of each batch were 
given. 
Weight variations Specification  
Table No: 10. Weight variations Specification as per IP 
Average weight of tablets(mg) Maximum % difference allowed 
Less than 80 10 
80- 250 7.5 
Above 250 5 
2. Dimensions 
Control of physical dimension of the tablets thickness is essential for consumer 
acceptance and to maintain tablet to tablet uniformity. The dimensional specifications 
were measured using digital Vernier calipers. The thickness of tablets is mostly related to 
the tablet hardness can be used as initial control parameter. 
Six tablets were randomly selected from each batch and their thickness was 
measured by using Digital Vernier caliper. 
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3. Hardness20 
It is determined to get perfect compactness during shipping, coating, and 
packaging and to get proper shape and design. Hardness was measured by using hardness 
tester. (Pfizer hardness tester) for each batch six tablets were tested. The force required to 
break the tablet is recorded by the unit is Kg/cm2. 
Observation: 
The measured hardness of tablets of each batch was range from 6-16Kg/cm2. 
 
4. Friability 
Twenty tablets were weighed and placed in the Roche friabilator and apparatus 
was rotated at 25 rpm for every 4 minutes. After revolution the tablets were dedusted and 
weighed again. The percentage friability was measured using the formula, 
%F= {1-(Wt /W)} x 100 
                    Where,    %F=friability in percentage 
                                     W=initial weight of tablets after revolution 
Observation: 
All the formulated batches were found under acceptable limit of 0.1- 0.6 as 
specified in IP. 
 
5. Buoyancy Lag Time22 
It is determined in order to assess the time taken by the dosage form to float on 
the top of the dissolution medium, after it is placed in the medium. These parameters can 
be measured as a part of the dissolution test. 
The results were tabulated in table. 
 
6. Floating Time23 
Test for buoyancy is usually performed in SGF-Simulated Gastric Fluid 
maintained at 370C. The time for which the dosage form continuously floats on the 
dissolution media is termed as floating time. 
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7. Dissolution study: 
Preparation of buffer: 
Measure 8.5 ml of HCL in a 1000 ml volumetric flask and make up the volume 
to 1000 ml using distilled water. 
 
Requirements: 
Medium: 0.1N Hcl 
Volume: 900 ml 
Apparatus: USP II (paddle) 
RPM: 100 
Time: upto 12 hrs 
Temperature: 370 c + 0.50c 
λmax :  266 nm 
 Perform the test on six tablets one tablet in each dissolution vessel containing 900 
ml of 0.1 N Hcl maintained at 370c + 0.50c. at specific time withdrawn required amount 
of sample and replace same amount of 0.1N HCL (maintain sink condition), then 
absorbance was taken and calculate percentage release. 
% purity = absorbance * 900 * dilution * 100 
           Slope * 1000 * label claim 
 
8. Assay: 
        Crush 20 tablets and weigh equivalent to 20 mg famotidine and dissolved in 0.1N 
Hcl and make up the volume to 100 ml. From that, withdraw 10 ml and diluted to 100 ml 
with 0.1 N Hcl. Read the absorbance at 266 nm in UV spectrophotometer. 
9. Kinetics of drug release 
 The invitro dissolution profile of all batches were fitted to Zero order,  first 
order, Higuchi model and Koresmeyer-Peppas model to ascertain the kinetic modeling 
of drug release. Correlation coefficient (R2) values were calculated for linear curves 
obtained by the regression analysis of the above plot. 
 
 Zero-order kinetic model – Cumulative % drug released Vs time. 
 First-order kinetic model – log cumulative % drug remaining Vs time. 
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 Higuchi model - Cumulative % drug released Vs square root of time. 
 Korsmeyer-Peppas model - log cumulative % drug released Vs log time. 
Zero-order kinetics 
 Zero order release would be predicted by the following equation: 
   At = Ao-Kot 
 At -  Drug release at time‘t’ 
 Ao - Initial drug concentration 
 Ko - Zero-order rate constant (hr-1) 
  
 When the data plotted as cumulative % drug release Vs time and the plot is 
linear, then the data obeys zero-order equal to Ko. 
 
 
First order kinetics: 
First order release would be predicted by the following equation: 
 [ 
Log C = log Co – Kt / 2.303 
 
 C - Amount of drug remained at time‘t’ 
 Co - Initial drug concentration 
 K - First-order rate constant (hr-1) 
When data is plotted as log cumulative % remaining Vs time yields a straight line, 
and then the release obeys first order kinetics.  The constant ‘K’ obtained by multiplying 
2.303 with the slope values. 
 
Higuchi’s Model: 
Drug release from the matrix devices by diffusion has been described by  
Following Higuchi’s classical diffusion equation: 
 
  Q  = [Dε/τ (2A-εCS) CSt] ½ 
 Q  -  Amount of drugreleased at time‘t’ 
 D  - Diffusion coefficient of the drug in the matrix 
 A  - Total amount of drug in unit volume of matrix 
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 CS - The solubility of drug in the matrix 
 ε - Porosity of the matrix 
 τ - Tortuosity 
 t - Time at which amount of drug released 
When the data is plotted as Cumulative % drug released Vs square root of time 
yields a straight line, indicating that drug release follows diffusion mechanisms.  The 
slope is equal to ‘K’. 
 
Korsmeyer – Peppas model: 
 To study the mechanism of drug release from the microspheres, the invitro 
release data were fitted to the well-known exponential equation (Korsmeyer – Peppas 
model), which is often used to describe the drug release behaviour from polymeric 
systems. 
Mt/Mα = Ktn 
 
 
Mt/Mα  - The fraction of drug released at time‘t’ 
     K-Constant incorporating structural and geometrical characteristics    of 
the drug/polymer system 
 N-Diffusion exponent related to the mechanism of drug release 
When the data plotted as log % drug released Vs log time yields a   straight 
line with a slope equal to ‘n’ and the ‘K’ can be obtained from y-intercept.  
 
Mechanism of drug release as per Korsmeyer - Peppas equation / Peppas 
model. 
Table. No. 12: Mechanism of drug release 
 
S.No n value Drug release 
1 0 –0.5 Fickian release 
2 0.5 – 1.0 Non-Fickian release 
3 >1.0 Class II transport 
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12. RESULT AND DISCUSSION 
12.1. Preformulation studies: 
12.1.1. Organoleptic properties: 
 The tests were performed as per the procedure. The results were tabulated 
below. 
Table.no.13. organoleptic properties 
Test Specifications/limits Observations 
Colour White to pale yellow White powder 
odour Odourless Odourless 
The result complies as per specifications. 
12.1.2. Physical properties: 
Angle of repose: 
          It was determined as per procedure. The results were tabulated below. 
Table.no.14. flow properties 
Material Angle of repose 
Famotidine 27.140 
The results show that the drug having poor flow. 
Bulk density and tapped density: 
It was determined as per procedure. The results were tabulated below. 
Table no. 15.bulk density and tapped density 
Material Bulk density(gm/ml) Tapped density(gm/ml) 
Famotidine 0.48 0.44 
Powder compressibility: 
It was determined as per procedure. The results were tabulated below. 
Table no. 16.powder compressibility 
Material Compressibility index Hausner’s ratio 
Famotidine 11.27 1.44 
Melting point: 
It was determined as per procedure. The results were tabulated below. 
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Table no.17. Melting point 
Material Melting point range Result 
Famotidine 163.5 °  C 163 0c 
The result indicates that the Famotidine drug was pure one. 
12.1.3. SOLUTION PROPERTIES 
PH of the solution: 
It was determined as per procedure. The results were tabulated below. 
Table no. 18. PH of the solution 
Material test Specification observation 
Famotidine PH 5-6(1% aqueous 
solution) 6.22 
 
The result indicates that the Famotidine drug was pure one. 
Solubility: 
It was determined as per procedure. The results were tabulated below. 
Table no.19 . Solubility 
Material test Specification observation 
Famotidine Solubility 
Freely soluble in glacial acetic acid, 
slightly soluble in methanol, very 
slightly soluble in water, and 
practically insoluble in ethanol. 
Complies 
 
The result complies as per specification. 
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12.1.4. Drug-excipient compatibility studies: 
Discussion: 
The FT-IR peaks were observed that there is no change in the spectrum representing that 
there is no interaction between the drug and polymers and other excipients. These peaks 
play a vital role with respect to drug release. 
Table no. 20. Drug-excipient compatibility 
Drug + Excipients Initial After 1 month at Compatible 
400C/75%RH 600C 
Drug White powder No change No change Yes 
Drug + HPMC K4 M White powder No change No change Yes 
Drug + HPMC K15 M White powder No change No change Yes 
Drug + HPMC K100 M White powder No change No change Yes 
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Fig. no. 16. FTIR of Famotidine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER-12                                                                                                    RESULTS & DISCUSSION  
  
Dept. of Pharmaceutics                            79                         J.K.K.Nattraja College of Pharmacy  
 
 
 
 
 
 
 
Fig. no. 17. FTIR of HPMC  
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Fig. no.  18. FTIR of Famotidine + excipients 
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12.1.5. Evaluation of granules: 
Table.no.21. showing results of angle of repose, bulk and tapped density, Carr’s 
index, hausner ratio 
Batch 
no. 
Angle of 
repose(0) 
Bulkdensity 
(gm/ml) 
Tappeddensity 
(gm/ ml) 
Carr’s 
index(%) 
Hausner 
ratio 
F1 
26 o 32' 0.2891 0.3503 14.04 1.21 
F2 24o  64' 0.2845 0.3394 15.68 1.22 
F3 28o 59' 0.2924 0.3349 11.94 1.13 
F4 26o12' 0.2875 0.3446 13.96 1.16 
F5 23o 62' 0.2862 0.3420 15.13 1.19 
F6 24o74' 0.2677 0.3214 13.92 1.15 
F7 24 o 77' 0.2743 0.3242 15.42 1.19 
F8 26 o 56' 0.2847 0.3177 10.38 1.11 
 
Discussion:  
The angle of repose for the formulations F1-F8 was found to be in the range 
230.62’ to 280.59’ shows good flow. 
Compressibility index for the formulations F1-F8 found between 10.38% to 
15.6% indicating that the blend has good flow property for compression. 
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12.1.6. EVALUATION OF FAMOTIDINE TABLETS 
Table no. 22.weight variation and friability 
Batch no. Weight variation Friability Content uniformity 
F1 + 1.52 0.23 99.65 
F2 ±2.37 0.34 99.74 
F3 + 1.87 0.21 98.34 
F4 + 1.41 0.27 99.44 
F5 ±1.86 0.18 100.38 
F6 ±2.56 0.28 99.96 
F7 +2.35 0.29 99.47 
F8 ±1.93 0.19 99.35 
Discussion: 
The weight variation of the above tablets are in the range of + 1.23 to 3.09 
%(below 5%) complying with the pharmacopoeial standards. 
The friability of the tablets are in the range of 0.18 % to 0.34% (below 1%) 
complying with the pharmacopoeial standards. 
The content uniformity of the tablets are in the range of 99.37 to 100.38% 
complying with the pharmacopoeial standards. 
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12.1.7. THICKNESS AND HARDNESS: 
Table no. 23.Thickness and hardness 
Batch no. Thickness(mm) Hardness(kg/cm2) 
F1 5.2+0.01 6.2 
F2 5.1+0.02 7.1 
F3 5.3+0.01 6.5 
F4 5.1+0.03 6.9 
F5 5.2+0.01 6.3 
F6 5.3+0.04 7.2 
F7 5.5+0.01 7.5 
F8 5.3+0.01 6.4 
 
Discussion: 
The thickness of the formulations was found to be in the range of 5.1+0.01 to 
5.5+0.01 mm. 
The hardness of the tablets was found to be in the range of 6.2 to 7.5 kg/cm2 
indiacting a satisfactory mechanical strength. 
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12.1.8. BUOYANCY LAG TIME AND TOTAL FLOATING TIME 
Table no. 24. Showing buoyancy lag time and total floating time 
Batch no. Buoyancy lag time Total buoyancy time(hrs) 
F1 624 15 
F2 96 3 
F3 90 6 
F4 84 12 
F5 171 5 
F6 63 10 
F7 44 15 
F8 39 14 
Discussion:  
From the results formulations F1, F4, F7, F8 shows good buoyancy,all 
formulations showed buoyancy  upto 12 hrs. 
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12.2.In-vitro release profile: 
Table.no.25. in-vitro release profile 
 
Time 
(hrs) 
 
F1 F2 F3 F4 F5 F6 F7 F8 
1 8.65 24.79 15.13 7.24 21.32 13.76 5.91 12.25 
2 13.12 58.12 34.67 12.09 43.13 24.27 11.64 16.79 
3 17.75 95.39 46.21 17.62 67.08 30.14 17.08 22.47 
4 25.34  63.90 23.98 96.34 39.51 25.42 26.75 
5 29.59  76.39 31.56  46.24 29.32 30.54 
6 34.23  96.14 39.34  53.69 31.13 37.67 
7 41.09   47.87  67.76 36.41 43.34 
8 47.23   55.23  80.09 40.69 49.50 
9 53.98   64.42  89.13 46.86 54.71 
10 58.14   73.7  97.43 53.63 60.92 
11 61.17   84.54   57.20 68.43 
12 67.91   96.78   62.32 72.19 
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Fig. no. 19. Showing in-vitro drug release profile for F1-F8 formulations 
From the in-vitro dissolution study of all formulations, formulation F1 gave 
84% release at the end of 24th hour, hence F1 have choosen as best formulation. 
 
Fig. no. 20. Showing in-vitro release profile of best formulation(F10) 
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12.3. DRUG RELEASE KINETICS: 
Fig. No.26: Drug release kinetics: 
 
Time 
(Hr) 
cumulative 
% drug 
released 
% drug 
remaining 
Square 
root 
time 
log Cumu % 
drug 
remainining 
log 
time 
log 
Cumu 
% drug 
released 
% Drug 
released 
0 0 100 0.000 2.000 0.000 0.000 100 
1 7.24 92.76 1.000 1.967 0.000 0.860 7.24 
2 12.09 87.91 1.414 1.944 0.301 1.082 4.85 
3 17.62 82.38 1.732 1.916 0.477 1.246 5.53 
4 23.98 76.02 2.000 1.881 0.602 1.380 6.36 
5 31.56 68.44 2.236 1.835 0.699 1.499 7.58 
6 39.34 60.66 2.449 1.783 0.778 1.595 7.78 
7 47.87 52.13 2.646 1.717 0.845 1.680 8.53 
8 55.23 44.77 2.828 1.651 0.903 1.742 7.36 
9 64.42 35.58 3.000 1.551 0.954 1.809 9.19 
10 73.7 26.3 3.162 1.420 1.000 1.867 9.28 
11 84.54 15.46 3.317 1.189 1.041 1.927 10.84 
12 96.78 3.22 3.464 0.508 1.079 1.986 12.24 
 
Fig. no. 21: Zero Order Kinetic Model 
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Fig. no. 22: First Order Release Kinetics 
 
 
 
Fig. no. 23: Higuchi model 
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Fig. no. 24: Korsemeyer Peppas Model 
 
 
 
 Table.No:27. Regression coefficient of F10 
Formulation 
Regression coefficient (R2 ) value 
Zero-order First order Higuchi Korsmeyer – Peppas (n value) 
Famotidine 
tables 0.9955 0.7328 0.9684 0.84 (0.8274) 
 
N value = 0.8274 
The regression coefficient values and n values show that the drug releases 
follow Non - Fickian release. 
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        Fig. No: 25. Buoyancy of formulation F4. 
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13. SUMMARY 
 
The present study involves the formulation and evaluation of gastroretentive 
drug delivery of Famotidine tablets. This type of drug delivery helps to retain the 
drug in the stomach. The swelling property of the formulation helps to retain the drug 
in the stomach, by swelling to such an extent so that cannot pass out of the stomach. 
  
 Preformulation studies which include Organoleptic properties, Bulk and 
Tapped densities, Carr’s index, Hausner’s ratio, Melting point, PH , Solubility, were 
carried out are as per  IP specifications. 
 
 Drug-excipient compatibility studies were performed which shows that there 
is no interaction between drug and polymers. 
 
 Evaluation studies have been performed for tablets include friability, 
hardness, weight variation, content uniformity, buoyancy studies are as per IP 
specifications. 
 
 Drug release studies have been performed by using 0.1N Hcl for 12 hrs. These 
studies have shown that the formulation F4 gave better drug release upto 12 hrs. 
which is formulated with HPMC K100 M.  
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14. CONCLUSION 
Floating tablets with sustained release characteristics offer critical advantages 
such as, site specificity with improved absorption and efficacy. This technology can 
be inculcated to various medicaments which have stomach as the major site of 
absorption. 
 
Moreover, floating mechanism doesn’t require any complex technology and 
hence, easy to adopt. Hence, it can be employed in various developmental studies 
based on requirement. 
 
Drugs that have poor bio-availability because of their limited absorption to 
the upper gastrointestinal tract can be delivered efficiently into FDDS.  Thereby 
maximizing  their  absorption  and improving their absolute bioavailability. The 
floating concept can also be utilized in the development to treating various diseases.  
 
Buoyant delivery system considered as a beneficial strategy for the treatment 
of gastric and duodenal cancers. 
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